data_1mqz_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1mqz _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.752 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 4.3 pp . . . . . 0 CA--C 1.548 0.872 0 N-CA-C 114.269 1.211 . . . . 3.1000000000000001 114.269 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.752 ' HD3' ' HG ' ' A' ' 5' ' ' LEU . 28.4 Cg_exo -63.51 157.03 53.15 Favored 'Trans proline' 0 C--N 1.361 1.233 0 C-N-CA 121.84 1.694 . . . . 2.4199999999999999 112.806 -178.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -123.13 95.18 0.53 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 121.21 -0.519 . . . . 4.79 112.036 178.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 179.87 -152.86 11.29 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.895 -0.669 . . . . 5.4800000000000004 112.078 -179.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -90.93 -35.82 7.0 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.782 -0.723 . . . . 4.0899999999999999 111.678 178.235 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.1 87.67 0.85 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 110.944 -0.862 . . . . 1.76 110.944 175.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 23.8 m -123.99 163.22 23.99 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.638 0 CA-C-O 121.966 0.888 . . . . 1.25 112.24 -173.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.312 -1.054 0 CA-C-N 113.379 -1.737 . . . . 0.80000000000000004 109.957 173.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 . . . . . 0 N--CA 1.452 -0.342 0 CA-C-O 120.698 0.285 . . . . 2.3599999999999999 110.86 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.431 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 8.1 m -138.37 -83.89 0.29 Allowed 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.103 0.408 . . . . 0.29999999999999999 112.103 178.355 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.431 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 29.9 pt . . . . . 0 C--N 1.341 0.234 0 CA-C-N 115.819 -0.628 . . . . 2.4300000000000002 112.076 -167.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.774 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 3.4 pp . . . . . 0 CA--C 1.547 0.837 0 N-CA-C 113.175 0.805 . . . . 3.1000000000000001 113.175 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.774 ' HD3' ' HG ' ' A' ' 5' ' ' LEU . 68.6 Cg_endo -96.27 -159.97 0.06 OUTLIER 'Trans proline' 0 C--N 1.361 1.225 0 C-N-CA 121.867 1.711 . . . . 2.4199999999999999 112.441 -178.163 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -112.49 -86.96 1.62 Allowed Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.637 -0.792 . . . . 4.79 111.991 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 63.69 37.32 94.55 Favored Glycine 0 N--CA 1.452 -0.269 0 N-CA-C 111.394 -0.682 . . . . 5.4800000000000004 111.394 -177.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.05 -79.55 0.36 Allowed Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 110.899 -0.88 . . . . 4.0899999999999999 110.899 -172.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.79 -77.01 0.46 Allowed Glycine 0 N--CA 1.442 -0.916 0 N-CA-C 110.801 -0.92 . . . . 1.76 110.801 172.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 10.2 m -149.49 173.55 1.35 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.747 0 CA-C-O 121.561 0.696 . . . . 1.25 110.504 175.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.415 ' CB ' ' HD2' ' A' ' 6' ' ' PRO . 1.0 OUTLIER . . . . . 0 C--N 1.303 -1.434 0 CA-C-N 113.571 -1.649 . . . . 0.80000000000000004 108.65 168.273 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 43.9 tp10 . . . . . 0 N--CA 1.454 -0.243 0 CA-C-O 120.791 0.329 . . . . 2.3599999999999999 110.836 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.425 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 7.6 m -141.74 -82.85 0.21 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.101 0.477 . . . . 0.29999999999999999 111.693 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.425 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER . . . . . 0 N--CA 1.452 -0.355 0 CA-C-N 114.771 -1.104 . . . . 2.4300000000000002 111.179 -168.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.688 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 4.9 mp . . . . . 0 CA--C 1.54 0.579 0 N-CA-C 112.808 0.67 . . . . 3.1000000000000001 112.808 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.688 ' HD3' ' HB2' ' A' ' 5' ' ' LEU . 5.0 Cg_exo -79.76 164.25 23.18 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 122.64 2.227 . . . . 2.4199999999999999 112.496 -174.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.578 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -70.98 -93.73 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.854 -0.612 . . . . 4.79 112.238 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.8 35.79 90.69 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 121.158 -0.544 . . . . 5.4800000000000004 112.578 178.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 108.43 34.29 2.72 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.742 -0.742 . . . . 4.0899999999999999 111.467 -176.282 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.578 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 116.72 -92.4 0.56 Allowed Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 111.446 -0.661 . . . . 1.76 111.446 -176.441 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.523 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 6.5 m -150.55 154.11 9.26 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.723 0 CA-C-O 121.615 0.722 . . . . 1.25 110.188 176.387 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.541 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.305 -1.365 0 CA-C-N 114.115 -1.402 . . . . 0.80000000000000004 109.342 172.104 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 13.8 tp10 . . . . . 0 N--CA 1.453 -0.285 0 CA-C-O 120.918 0.389 . . . . 2.3599999999999999 110.616 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.412 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 6.0 m -131.75 -86.56 0.48 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.336 -0.393 . . . . 0.29999999999999999 111.873 -177.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.412 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.3 OUTLIER . . . . . 0 CA--C 1.533 0.316 0 CA-C-N 115.036 -0.984 . . . . 2.4300000000000002 111.348 -168.596 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.626 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 1.5 pt? . . . . . 0 CA--C 1.542 0.661 0 N-CA-C 114.134 1.161 . . . . 3.1000000000000001 114.134 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.633 ' HD2' ' CB ' ' A' ' 12' ' ' CYS . 20.8 Cg_exo -68.72 151.51 74.59 Favored 'Trans proline' 0 C--N 1.358 1.066 0 C-N-CA 121.647 1.564 . . . . 2.4199999999999999 112.23 -177.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.417 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -110.96 54.1 0.55 Allowed Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.761 -0.654 . . . . 4.79 112.312 -178.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -112.34 80.81 0.28 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.746 -0.74 . . . . 5.4800000000000004 111.278 177.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.1 28.51 5.82 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.159 -0.776 . . . . 4.0899999999999999 111.159 -175.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.417 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 108.24 -113.57 3.89 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.181 -0.768 . . . . 1.76 111.181 -176.046 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.8 m -132.26 156.14 42.15 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.77 0 CA-C-O 121.745 0.783 . . . . 1.25 110.458 173.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.633 ' CB ' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.304 -1.381 0 CA-C-N 113.812 -1.54 . . . . 0.80000000000000004 110.323 174.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 . . . . . 0 N--CA 1.452 -0.356 0 CA-C-O 120.485 0.183 . . . . 2.3599999999999999 110.523 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.463 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 4.9 m -136.67 -84.93 0.34 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.94 -0.304 . . . . 0.29999999999999999 111.769 176.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.463 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 24.5 pt . . . . . 0 N--CA 1.451 -0.375 0 CA-C-N 115.773 -0.649 . . . . 2.4300000000000002 111.993 -167.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.471 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 6.5 mp . . . . . 0 CA--C 1.544 0.732 0 N-CA-C 114.936 1.458 . . . . 3.1000000000000001 114.936 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.749 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 21.6 Cg_endo -67.59 152.64 77.97 Favored 'Trans proline' 0 C--N 1.356 0.953 0 C-N-CA 121.851 1.701 . . . . 2.4199999999999999 112.823 -173.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.453 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -119.15 87.25 0.41 Allowed Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.804 -0.712 . . . . 4.79 112.851 -177.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -113.97 -43.34 0.8 Allowed Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.943 -0.863 . . . . 5.4800000000000004 110.943 175.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -119.35 36.97 3.31 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 109.893 -1.283 . . . . 4.0899999999999999 109.893 172.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.453 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 112.24 -89.09 0.52 Allowed Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 110.507 -1.037 . . . . 1.76 110.507 -172.126 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.688 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -151.35 150.4 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.956 0 CA-C-O 121.486 0.66 . . . . 1.25 110.088 173.112 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.749 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.303 -1.431 0 CA-C-N 114.127 -1.397 . . . . 0.80000000000000004 110.399 172.649 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 . . . . . 0 N--CA 1.454 -0.254 0 CA-C-O 120.836 0.351 . . . . 2.3599999999999999 110.887 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.463 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.7 m -136.55 -87.39 0.32 Allowed 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.681 -0.408 . . . . 0.29999999999999999 111.896 178.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.463 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.5 OUTLIER . . . . . 0 CA--C 1.535 0.376 0 CA-C-N 115.205 -0.907 . . . . 2.4300000000000002 111.105 -169.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.5 mp . . . . . 0 CA--C 1.541 0.632 0 N-CA-C 113.656 0.984 . . . . 3.1000000000000001 113.656 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.68 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 51.2 Cg_exo -61.08 146.1 98.09 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.18 1.92 . . . . 2.4199999999999999 113.283 -173.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.443 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -76.28 75.11 1.61 Allowed Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.535 -0.757 . . . . 4.79 113.004 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -119.31 75.98 0.3 Allowed Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 110.421 -1.072 . . . . 5.4800000000000004 110.421 174.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.51 39.5 5.3 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 110.518 -1.033 . . . . 4.0899999999999999 110.518 -171.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.443 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 93.73 -83.28 1.03 Allowed Glycine 0 N--CA 1.444 -0.819 0 N-CA-C 110.455 -1.058 . . . . 1.76 110.455 -172.304 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.2 m -132.84 149.33 31.79 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.814 0 CA-C-O 121.822 0.82 . . . . 1.25 110.987 173.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.68 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.303 -1.44 0 CA-C-N 113.211 -1.813 . . . . 0.80000000000000004 109.451 168.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 . . . . . 0 N--CA 1.454 -0.231 0 CA-C-O 120.776 0.322 . . . . 2.3599999999999999 110.659 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.439 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.4 m -134.58 -85.31 0.41 Allowed 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 112.123 0.416 . . . . 0.29999999999999999 112.123 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.439 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER . . . . . 0 CA--C 1.535 0.377 0 CA-C-N 115.431 -0.804 . . . . 2.4300000000000002 111.582 -168.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.553 ' HG ' ' CD ' ' A' ' 6' ' ' PRO . 1.1 pt? . . . . . 0 CA--C 1.546 0.796 0 N-CA-C 112.681 0.623 . . . . 3.1000000000000001 112.681 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.553 ' CD ' ' HG ' ' A' ' 5' ' ' LEU . 3.3 Cg_endo -91.97 -159.02 0.07 OUTLIER 'Trans proline' 0 C--N 1.366 1.462 0 C-N-CA 122.222 1.948 . . . . 2.4199999999999999 112.405 -175.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.43 38.76 1.42 Allowed Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 121.035 -0.603 . . . . 4.79 112.465 -177.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.17 -92.51 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.909 -0.663 . . . . 5.4800000000000004 111.893 179.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -81.74 80.98 1.7 Allowed Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 110.738 -0.945 . . . . 4.0899999999999999 110.738 173.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.71 -84.49 0.66 Allowed Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.273 -0.731 . . . . 1.76 111.273 -171.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.84 -88.48 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 120.941 0.401 . . . . 1.25 110.535 173.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 N--CA 1.441 -0.891 0 N-CA-C 107.74 -1.208 . . . . 0.80000000000000004 107.74 -174.476 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 . . . . . 0 N--CA 1.455 -0.212 0 CA-C-O 121.382 0.61 . . . . 2.3599999999999999 109.617 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 1.4 m -132.79 -69.32 0.57 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.54 -0.755 . . . . 0.29999999999999999 110.686 179.151 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 44.2 mm . . . . . 0 N--CA 1.447 -0.587 0 CA-C-N 114.04 -1.436 . . . . 2.4300000000000002 110.996 -169.741 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.568 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 1.0 OUTLIER . . . . . 0 CA--C 1.55 0.959 0 N-CA-C 114.589 1.329 . . . . 3.1000000000000001 114.589 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.96 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 3.6 Cg_exo -78.56 -168.69 0.65 Allowed 'Trans proline' 0 C--N 1.361 1.193 0 C-N-CA 122.154 1.903 . . . . 2.4199999999999999 111.775 -177.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.47 ' HA2' ' HA ' ' A' ' 11' ' ' VAL . . . -112.33 -91.2 1.97 Allowed Glycine 0 N--CA 1.442 -0.922 0 C-N-CA 120.465 -0.874 . . . . 4.79 112.586 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.24 38.51 96.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.959 -0.639 . . . . 5.4800000000000004 112.078 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.72 36.72 1.37 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.939 -0.648 . . . . 4.0899999999999999 111.483 -175.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.415 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 114.35 -88.96 0.49 Allowed Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 111.319 -0.712 . . . . 1.76 111.319 -175.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.619 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 3.1 m -149.72 150.09 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.867 0 CA-C-O 121.745 0.783 . . . . 1.25 110.199 175.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.96 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.304 -1.371 0 CA-C-N 113.787 -1.551 . . . . 0.80000000000000004 109.927 171.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 21.1 tp10 . . . . . 0 N--CA 1.45 -0.437 0 CA-C-O 120.691 0.281 . . . . 2.3599999999999999 110.348 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.402 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 7.7 m -131.77 -82.96 0.51 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.126 0.417 . . . . 0.29999999999999999 112.126 176.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.402 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 28.6 pt . . . . . 0 N--CA 1.455 -0.176 0 N-CA-C 112.674 0.62 . . . . 2.4300000000000002 112.674 -167.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.476 ' N ' ' HD3' ' A' ' 6' ' ' PRO . 3.7 pp . . . . . 0 CA--C 1.552 1.035 0 N-CA-C 115.667 1.728 . . . . 3.1000000000000001 115.667 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.974 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 3.9 Cg_exo -83.74 158.18 14.03 Favored 'Trans proline' 0 C--N 1.36 1.167 0 C-N-CA 121.897 1.731 . . . . 2.4199999999999999 112.331 -176.712 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -109.73 73.53 0.21 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.92 -0.657 . . . . 4.79 112.563 -177.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -112.78 94.9 0.75 Allowed Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 111.301 -0.72 . . . . 5.4800000000000004 111.301 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 80.16 36.68 23.79 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 110.733 -0.947 . . . . 4.0899999999999999 110.733 -171.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.412 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 108.16 -93.1 0.78 Allowed Glycine 0 N--CA 1.443 -0.838 0 N-CA-C 111.082 -0.807 . . . . 1.76 111.082 -175.106 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 8.5 m -146.94 154.31 12.0 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.925 0 CA-C-O 121.707 0.765 . . . . 1.25 110.26 174.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.974 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.302 -1.498 0 CA-C-N 113.997 -1.456 . . . . 0.80000000000000004 109.358 171.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 . . . . . 0 N--CA 1.453 -0.292 0 CA-C-O 120.676 0.274 . . . . 2.3599999999999999 111.098 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.452 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.1 m -133.75 -86.21 0.43 Allowed 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.28 -0.568 . . . . 0.29999999999999999 112.498 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.452 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER . . . . . 0 CA--C 1.538 0.497 0 CA-C-N 115.045 -0.98 . . . . 2.4300000000000002 111.879 -167.194 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.513 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 9.9 mp . . . . . 0 CA--C 1.538 0.489 0 N-CA-C 113.163 0.801 . . . . 3.1000000000000001 113.163 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.647 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 52.9 Cg_exo -55.87 146.12 69.35 Favored 'Trans proline' 0 C--N 1.358 1.06 0 C-N-CA 122.144 1.896 . . . . 2.4199999999999999 112.872 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -127.39 97.73 0.48 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.086 -0.578 . . . . 4.79 112.749 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -179.81 -152.22 10.61 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.885 -0.674 . . . . 5.4800000000000004 111.591 179.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.47 -32.28 68.02 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.079 -0.582 . . . . 4.0899999999999999 111.81 177.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -110.97 99.01 1.09 Allowed Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.499 -0.64 . . . . 1.76 111.499 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.9 m -114.8 153.75 16.26 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.75 0 CA-C-O 122.044 0.926 . . . . 1.25 112.03 -176.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.647 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.308 -1.213 0 CA-C-N 113.392 -1.731 . . . . 0.80000000000000004 109.563 170.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 . . . . . 0 N--CA 1.454 -0.255 0 CA-C-O 120.634 0.255 . . . . 2.3599999999999999 110.576 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.484 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 4.6 m -144.52 -85.34 0.13 Allowed 'General case' 0 C--O 1.233 0.212 0 N-CA-C 112.024 0.379 . . . . 0.29999999999999999 112.024 177.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.484 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.5 OUTLIER . . . . . 0 CA--C 1.537 0.469 0 CA-C-N 114.638 -1.164 . . . . 2.4300000000000002 112.386 -166.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.954 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 85.2 mt . . . . . 0 CA--C 1.536 0.411 0 CA-C-O 119.824 -0.131 . . . . 3.1000000000000001 111.123 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.954 ' HD3' ' HB2' ' A' ' 5' ' ' LEU . 27.4 Cg_exo -63.46 167.07 13.78 Favored 'Trans proline' 0 C--N 1.356 0.963 0 C-N-CA 122.367 2.045 . . . . 2.4199999999999999 112.381 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -107.53 -25.08 6.15 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.91 -0.662 . . . . 4.79 112.399 -179.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -124.19 149.74 16.95 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.55 -0.833 . . . . 5.4800000000000004 112.384 179.389 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 66.88 -128.69 29.25 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 121.078 -0.582 . . . . 4.0899999999999999 112.228 179.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.423 ' O ' ' HG2' ' A' ' 6' ' ' PRO . . . -66.96 93.66 0.22 Allowed Glycine 0 N--CA 1.449 -0.452 0 N-CA-C 111.367 -0.693 . . . . 1.76 111.367 176.743 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.701 ' O ' ' HB3' ' A' ' 12' ' ' CYS . 2.2 m -88.57 -16.81 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.846 0 N-CA-C 113.186 0.809 . . . . 1.25 113.186 -171.513 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.701 ' HB3' ' O ' ' A' ' 11' ' ' VAL . 1.7 t . . . . . 0 C--N 1.322 -0.594 0 O-C-N 124.232 0.958 . . . . 0.80000000000000004 108.809 -173.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.6 tp10 . . . . . 0 N--CA 1.451 -0.378 0 CA-C-O 120.791 0.329 . . . . 2.3599999999999999 110.603 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.458 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 7.8 m -142.91 -82.03 0.19 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.006 0.431 . . . . 0.29999999999999999 111.829 177.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.458 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.2 OUTLIER . . . . . 0 CA--C 1.534 0.348 0 CA-C-N 114.492 -1.231 . . . . 2.4300000000000002 111.678 -167.398 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.464 ' HA ' HD21 ' A' ' 5' ' ' LEU . 73.7 mt . . . . . 0 CA--C 1.536 0.435 0 N-CA-C 111.541 0.2 . . . . 3.1000000000000001 111.541 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.712 ' HG2' ' HA ' ' A' ' 11' ' ' VAL . 36.3 Cg_endo -65.67 154.9 71.8 Favored 'Trans proline' 0 C--N 1.354 0.821 0 C-N-CA 121.806 1.671 . . . . 2.4199999999999999 111.992 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -114.85 -27.46 3.23 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.791 -0.718 . . . . 4.79 112.12 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.17 153.03 17.0 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.811 -0.709 . . . . 5.4800000000000004 112.179 178.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 72.98 -141.51 30.43 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.038 -0.601 . . . . 4.0899999999999999 112.561 179.567 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -69.33 90.11 0.28 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 121.407 -0.425 . . . . 1.76 112.249 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.712 ' HA ' ' HG2' ' A' ' 6' ' ' PRO . 35.7 m -95.84 160.74 2.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.93 0.872 . . . . 1.25 112.178 -175.546 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.311 -1.066 0 CA-C-N 113.247 -1.797 . . . . 0.80000000000000004 110.061 175.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 73.9 tt0 . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 120.705 0.288 . . . . 2.3599999999999999 110.666 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.44 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 10.0 m -136.86 -84.71 0.34 Allowed 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 111.843 0.312 . . . . 0.29999999999999999 111.843 176.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.44 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 31.4 pt . . . . . 0 N--CA 1.45 -0.44 0 CA-C-N 115.738 -0.665 . . . . 2.4300000000000002 112.072 -168.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.411 ' HA ' HD21 ' A' ' 5' ' ' LEU . 96.8 mt . . . . . 0 CA--C 1.539 0.542 0 N-CA-C 112.983 0.734 . . . . 3.1000000000000001 112.983 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.454 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 29.1 Cg_endo -63.78 150.88 87.42 Favored 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 121.856 1.704 . . . . 2.4199999999999999 112.333 -178.695 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.484 ' HA2' HG11 ' A' ' 11' ' ' VAL . . . -150.2 50.47 0.54 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.951 -0.642 . . . . 4.79 112.28 -177.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.24 34.82 3.55 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.775 -0.726 . . . . 5.4800000000000004 112.405 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.4 -89.48 0.49 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.681 -0.771 . . . . 4.0899999999999999 111.852 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.45 89.26 0.72 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.788 -0.72 . . . . 1.76 111.304 174.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.484 HG11 ' HA2' ' A' ' 7' ' ' GLY . 30.5 m -89.41 162.44 2.53 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.797 0 CA-C-O 122.205 1.002 . . . . 1.25 111.809 -174.125 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.454 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.432 -1.37 0 CA-C-N 113.524 -1.671 . . . . 0.80000000000000004 109.235 171.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 . . . . . 0 N--CA 1.454 -0.256 0 N-CA-C 109.678 -0.49 . . . . 2.3599999999999999 109.678 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.456 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 1.5 m -129.23 -86.34 0.55 Allowed 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.739 -0.664 . . . . 0.29999999999999999 110.342 175.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.456 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 28.4 mm . . . . . 0 N--CA 1.448 -0.566 0 CA-C-N 114.702 -1.135 . . . . 2.4300000000000002 111.558 -175.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.578 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 7.9 mp . . . . . 0 N--CA 1.467 0.409 0 N-CA-C 112.53 0.567 . . . . 3.1000000000000001 112.53 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.705 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 14.8 Cg_exo -68.7 92.58 0.43 Allowed 'Trans proline' 0 C--N 1.355 0.921 0 C-N-CA 122.074 1.849 . . . . 2.4199999999999999 111.64 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.758 ' HA2' HG13 ' A' ' 11' ' ' VAL . . . -103.07 83.88 0.45 Allowed Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.81 -0.709 . . . . 4.79 112.119 -177.404 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -170.87 86.07 0.08 OUTLIER Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 111.466 -0.654 . . . . 5.4800000000000004 111.466 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 70.86 -90.6 0.41 Allowed Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 111.456 -0.658 . . . . 4.0899999999999999 111.456 -175.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.41 99.96 0.77 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.858 -0.687 . . . . 1.76 111.425 173.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.758 HG13 ' HA2' ' A' ' 7' ' ' GLY . 33.9 m -113.64 152.66 15.3 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.702 0 CA-C-O 121.995 0.902 . . . . 1.25 111.883 -175.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.705 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.306 -1.29 0 CA-C-N 113.294 -1.776 . . . . 0.80000000000000004 108.866 169.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 . . . . . 0 N--CA 1.452 -0.372 0 N-CA-C 109.982 -0.377 . . . . 2.3599999999999999 109.982 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.415 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 34.6 m -134.9 -87.82 0.37 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.332 -0.394 . . . . 0.29999999999999999 111.569 175.666 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.415 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 4.1 tt . . . . . 0 CA--C 1.535 0.388 0 CA-C-N 115.212 -0.904 . . . . 2.4300000000000002 112.989 -170.407 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.462 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 95.7 mt . . . . . 0 CA--C 1.537 0.474 0 N-CA-C 112.379 0.511 . . . . 3.1000000000000001 112.379 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HD2' ' N ' ' A' ' 5' ' ' LEU . 20.3 Cg_endo -61.2 144.04 98.75 Favored 'Trans proline' 0 C--N 1.356 0.924 0 C-N-CA 122.067 1.844 . . . . 2.4199999999999999 112.244 -179.258 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -129.18 91.36 0.32 Allowed Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.034 -0.603 . . . . 4.79 112.437 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 175.96 -155.87 20.36 Favored Glycine 0 N--CA 1.449 -0.496 0 N-CA-C 111.276 -0.729 . . . . 5.4800000000000004 111.276 179.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.11 93.8 0.78 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.832 -0.699 . . . . 4.0899999999999999 111.75 177.052 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.2 77.96 0.79 Allowed Glycine 0 N--CA 1.444 -0.801 0 N-CA-C 111.011 -0.835 . . . . 1.76 111.011 -175.405 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 21.8 m -109.1 167.02 4.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 122.052 0.929 . . . . 1.25 112.339 -175.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.309 -1.153 0 CA-C-N 112.961 -1.927 . . . . 0.80000000000000004 109.346 171.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 . . . . . 0 N--CA 1.455 -0.214 0 CA-C-O 120.872 0.368 . . . . 2.3599999999999999 110.462 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.413 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 14.4 m -143.4 -85.72 0.14 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.288 -0.414 . . . . 0.29999999999999999 111.814 179.116 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.498 ' O ' HD11 ' A' ' 19' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.452 -0.368 0 CA-C-N 114.981 -1.009 . . . . 2.4300000000000002 111.188 -168.307 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.444 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 97.8 mt . . . . . 0 CA--C 1.538 0.513 0 N-CA-C 111.866 0.321 . . . . 3.1000000000000001 111.866 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.444 ' HD2' ' N ' ' A' ' 5' ' ' LEU . 34.5 Cg_endo -65.26 151.45 85.31 Favored 'Trans proline' 0 C--N 1.356 0.93 0 C-N-CA 121.978 1.785 . . . . 2.4199999999999999 112.455 -179.696 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -127.41 29.92 4.17 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.046 -0.597 . . . . 4.79 112.287 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -116.27 -136.48 5.85 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.024 -0.608 . . . . 5.4800000000000004 112.345 -179.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -71.05 -85.01 0.18 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.149 -0.548 . . . . 4.0899999999999999 112.482 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.64 92.7 0.44 Allowed Glycine 0 N--CA 1.453 -0.225 0 C-N-CA 121.164 -0.541 . . . . 1.76 112.005 178.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.405 ' HA ' ' HG2' ' A' ' 6' ' ' PRO . 19.2 m -107.05 -177.19 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.628 0 CA-C-O 122.146 0.974 . . . . 1.25 112.242 -175.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.435 -1.211 0 CA-C-N 113.46 -1.7 . . . . 0.80000000000000004 109.344 176.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 . . . . . 0 CA--C 1.53 0.185 0 CA-C-O 120.815 0.34 . . . . 2.3599999999999999 110.792 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.464 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 4.8 m -138.67 -83.88 0.28 Allowed 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 112.175 0.435 . . . . 0.29999999999999999 112.175 177.311 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.464 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 21.5 pt . . . . . 0 N--CA 1.45 -0.457 0 CA-C-N 115.606 -0.725 . . . . 2.4300000000000002 111.969 -167.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.423 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 4.3 mm? . . . . . 0 CA--C 1.533 0.315 0 CA-C-O 119.816 -0.135 . . . . 3.1000000000000001 110.855 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.663 ' HB2' HG13 ' A' ' 11' ' ' VAL . 76.5 Cg_endo -75.11 149.72 36.66 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 121.415 1.41 . . . . 2.4199999999999999 111.133 174.081 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -133.79 28.49 3.22 Favored Glycine 0 CA--C 1.518 0.222 0 C-N-CA 120.64 -0.791 . . . . 4.79 112.928 -177.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.87 -90.31 2.16 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.835 -0.698 . . . . 5.4800000000000004 113.021 -178.098 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.8 -94.1 2.24 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.735 -0.745 . . . . 4.0899999999999999 112.534 -177.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.94 86.31 0.38 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 121.022 -0.609 . . . . 1.76 111.597 177.224 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.663 HG13 ' HB2' ' A' ' 6' ' ' PRO . 34.7 m -120.96 176.01 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.706 0 CA-C-O 122.096 0.951 . . . . 1.25 112.614 -171.379 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.432 -1.331 0 CA-C-N 112.785 -2.007 . . . . 0.80000000000000004 109.167 170.316 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 . . . . . 0 N--CA 1.453 -0.28 0 CA-C-O 120.776 0.322 . . . . 2.3599999999999999 110.33 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.493 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.5 m -143.79 -82.18 0.17 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.313 -0.403 . . . . 0.29999999999999999 111.737 177.24 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.493 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.1 OUTLIER . . . . . 0 CA--C 1.537 0.471 0 CA-C-N 115.324 -0.853 . . . . 2.4300000000000002 111.719 -167.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.659 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 40.6 t . . . . . 0 N--CA 1.477 0.883 0 CA-C-O 119.928 -0.082 . . . . 3.6499999999999999 110.963 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.659 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.803 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 28.6 t80 -58.25 106.61 0.39 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.686 -0.688 . . . . 1.24 110.951 -179.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.752 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 4.3 pp -70.48 -35.49 4.77 Favored Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 114.269 1.211 . . . . 3.1000000000000001 114.269 -173.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.752 ' HD3' ' HG ' ' A' ' 5' ' ' LEU . 28.4 Cg_exo -63.51 157.03 53.15 Favored 'Trans proline' 0 C--N 1.361 1.233 0 C-N-CA 121.84 1.694 . . . . 2.4199999999999999 112.806 -178.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -123.13 95.18 0.53 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 121.21 -0.519 . . . . 4.79 112.036 178.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 179.87 -152.86 11.29 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.895 -0.669 . . . . 5.4800000000000004 112.078 -179.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -90.93 -35.82 7.0 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.782 -0.723 . . . . 4.0899999999999999 111.678 178.235 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.1 87.67 0.85 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 110.944 -0.862 . . . . 1.76 110.944 175.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 23.8 m -123.99 163.22 23.99 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.638 0 CA-C-O 121.966 0.888 . . . . 1.25 112.24 -173.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -61.43 137.08 58.23 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 113.379 -1.737 . . . . 0.80000000000000004 109.957 173.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.624 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 51.9 tp -72.3 92.32 1.39 Allowed 'General case' 0 N--CA 1.444 -0.729 0 CA-C-O 121.364 0.602 . . . . 1.25 111.681 -176.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . 0.614 ' H ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -61.9 -32.69 73.09 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.286 -0.415 . . . . 2.3599999999999999 110.86 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.803 ' HB3' ' HB3' ' A' ' 3' ' ' PHE . 8.1 m -138.37 -83.89 0.29 Allowed 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.103 0.408 . . . . 0.29999999999999999 112.103 178.355 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.624 HG12 ' O ' ' A' ' 13' ' ' DBB . 29.9 pt -61.97 -31.68 51.95 Favored 'Isoleucine or valine' 0 C--N 1.341 0.234 0 CA-C-N 115.819 -0.628 . . . . 2.4300000000000002 112.076 -167.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . 0.452 ' HB2' ' C ' ' A' ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 41.9 t . . . . . 0 N--CA 1.479 0.991 0 CA-C-O 120.305 0.098 . . . . 3.6499999999999999 111.188 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.729 ' HA ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -67.03 106.37 1.93 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.269 -0.423 . . . . 1.24 110.662 176.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.774 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 3.4 pp -175.62 -35.12 0.0 OUTLIER Pre-proline 0 CA--C 1.547 0.837 0 N-CA-C 113.175 0.805 . . . . 3.1000000000000001 113.175 175.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.774 ' HD3' ' HG ' ' A' ' 5' ' ' LEU . 68.6 Cg_endo -96.27 -159.97 0.06 OUTLIER 'Trans proline' 0 C--N 1.361 1.225 0 C-N-CA 121.867 1.711 . . . . 2.4199999999999999 112.441 -178.163 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -112.49 -86.96 1.62 Allowed Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.637 -0.792 . . . . 4.79 111.991 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 63.69 37.32 94.55 Favored Glycine 0 N--CA 1.452 -0.269 0 N-CA-C 111.394 -0.682 . . . . 5.4800000000000004 111.394 -177.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.05 -79.55 0.36 Allowed Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 110.899 -0.88 . . . . 4.0899999999999999 110.899 -172.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.79 -77.01 0.46 Allowed Glycine 0 N--CA 1.442 -0.916 0 N-CA-C 110.801 -0.92 . . . . 1.76 110.801 172.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 10.2 m -149.49 173.55 1.35 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.747 0 CA-C-O 121.561 0.696 . . . . 1.25 110.504 175.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.415 ' CB ' ' HD2' ' A' ' 6' ' ' PRO . 1.0 OUTLIER -72.84 132.77 43.97 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 113.571 -1.649 . . . . 0.80000000000000004 108.65 168.273 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.448 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 36.0 tp -73.28 92.35 1.78 Allowed 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.003 0.43 . . . . 1.25 111.372 -178.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 43.9 tp10 -59.54 -31.28 69.26 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.034 -0.53 . . . . 2.3599999999999999 110.836 177.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.448 ' HB2' ' HA ' ' A' ' 13' ' ' DBB . 7.6 m -141.74 -82.85 0.21 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.101 0.477 . . . . 0.29999999999999999 111.693 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.729 HG12 ' HA ' ' A' ' 2' ' ' DBB . 0.4 OUTLIER -69.85 -31.72 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.355 0 CA-C-N 114.771 -1.104 . . . . 2.4300000000000002 111.179 -168.787 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.557 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 41.6 t . . . . . 0 N--CA 1.476 0.846 0 CA-C-O 119.959 -0.067 . . . . 3.6499999999999999 110.869 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.557 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.443 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 14.5 t80 -70.29 111.22 5.73 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.794 -0.639 . . . . 1.24 110.604 178.281 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . 0.616 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.688 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 4.9 mp -130.79 -54.71 0.03 OUTLIER Pre-proline 0 CA--C 1.54 0.579 0 N-CA-C 112.808 0.67 . . . . 3.1000000000000001 112.808 -175.124 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.688 ' HD3' ' HB2' ' A' ' 5' ' ' LEU . 5.0 Cg_exo -79.76 164.25 23.18 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 122.64 2.227 . . . . 2.4199999999999999 112.496 -174.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.578 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -70.98 -93.73 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.854 -0.612 . . . . 4.79 112.238 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.8 35.79 90.69 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 121.158 -0.544 . . . . 5.4800000000000004 112.578 178.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 108.43 34.29 2.72 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.742 -0.742 . . . . 4.0899999999999999 111.467 -176.282 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.578 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 116.72 -92.4 0.56 Allowed Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 111.446 -0.661 . . . . 1.76 111.446 -176.441 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.523 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 6.5 m -150.55 154.11 9.26 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.723 0 CA-C-O 121.615 0.722 . . . . 1.25 110.188 176.387 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.616 ' O ' ' HA ' ' A' ' 4' ' ' DBB . 0.0 OUTLIER -65.85 136.29 55.97 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 114.115 -1.402 . . . . 0.80000000000000004 109.342 172.104 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.463 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 39.5 tp -73.0 91.47 1.57 Allowed 'General case' 0 N--CA 1.443 -0.776 0 CA-C-O 121.205 0.526 . . . . 1.25 111.265 -177.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 13.8 tp10 -63.24 -35.25 79.7 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.918 0.389 . . . . 2.3599999999999999 110.616 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.463 ' HB2' ' HA ' ' A' ' 13' ' ' DBB . 6.0 m -131.75 -86.56 0.48 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.336 -0.393 . . . . 0.29999999999999999 111.873 -177.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.412 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.3 OUTLIER -67.8 -31.15 51.0 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 CA-C-N 115.036 -0.984 . . . . 2.4300000000000002 111.348 -168.596 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.604 ' HA ' ' C ' ' A' ' 2' ' ' DBB . 44.4 t . . . . . 0 N--CA 1.48 1.064 0 N-CA-C 111.513 0.19 . . . . 3.6499999999999999 111.513 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.604 ' C ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.491 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 4.1 t80 -79.68 94.06 5.64 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.585 -0.524 . . . . 1.24 109.585 177.507 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . 0.427 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.626 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 1.5 pt? -165.68 -38.44 0.0 OUTLIER Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 114.134 1.161 . . . . 3.1000000000000001 114.134 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.633 ' HD2' ' CB ' ' A' ' 12' ' ' CYS . 20.8 Cg_exo -68.72 151.51 74.59 Favored 'Trans proline' 0 C--N 1.358 1.066 0 C-N-CA 121.647 1.564 . . . . 2.4199999999999999 112.23 -177.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.417 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -110.96 54.1 0.55 Allowed Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.761 -0.654 . . . . 4.79 112.312 -178.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -112.34 80.81 0.28 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.746 -0.74 . . . . 5.4800000000000004 111.278 177.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.1 28.51 5.82 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.159 -0.776 . . . . 4.0899999999999999 111.159 -175.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.417 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 108.24 -113.57 3.89 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.181 -0.768 . . . . 1.76 111.181 -176.046 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.8 m -132.26 156.14 42.15 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.77 0 CA-C-O 121.745 0.783 . . . . 1.25 110.458 173.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.633 ' CB ' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -67.11 99.37 0.66 Allowed 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 113.812 -1.54 . . . . 0.80000000000000004 110.323 174.969 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.647 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 42.1 tp -73.04 88.62 1.41 Allowed 'General case' 0 N--CA 1.445 -0.693 0 CA-C-O 121.215 0.531 . . . . 1.25 111.286 -178.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . 0.477 ' H ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -61.56 -34.03 74.87 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 116.008 -0.542 . . . . 2.3599999999999999 110.523 178.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.491 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 4.9 m -136.67 -84.93 0.34 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.94 -0.304 . . . . 0.29999999999999999 111.769 176.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.647 HG12 ' O ' ' A' ' 13' ' ' DBB . 24.5 pt -63.82 -29.94 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.375 0 CA-C-N 115.773 -0.649 . . . . 2.4300000000000002 111.993 -167.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.488 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 51.5 t . . . . . 0 N--CA 1.478 0.97 0 CA-C-O 120.0 -0.048 . . . . 3.6499999999999999 110.957 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.611 ' HA ' HD12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.55 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 9.6 t80 -70.51 101.33 1.97 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.742 -0.663 . . . . 1.24 110.521 178.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . 0.67 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.471 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 6.5 mp -105.94 -39.72 0.17 Allowed Pre-proline 0 CA--C 1.544 0.732 0 N-CA-C 114.936 1.458 . . . . 3.1000000000000001 114.936 -170.608 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.749 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 21.6 Cg_endo -67.59 152.64 77.97 Favored 'Trans proline' 0 C--N 1.356 0.953 0 C-N-CA 121.851 1.701 . . . . 2.4199999999999999 112.823 -173.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.453 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -119.15 87.25 0.41 Allowed Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.804 -0.712 . . . . 4.79 112.851 -177.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -113.97 -43.34 0.8 Allowed Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.943 -0.863 . . . . 5.4800000000000004 110.943 175.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -119.35 36.97 3.31 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 109.893 -1.283 . . . . 4.0899999999999999 109.893 172.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.453 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 112.24 -89.09 0.52 Allowed Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 110.507 -1.037 . . . . 1.76 110.507 -172.126 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.688 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -151.35 150.4 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.956 0 CA-C-O 121.486 0.66 . . . . 1.25 110.088 173.112 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.749 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -59.9 147.12 39.72 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 114.127 -1.397 . . . . 0.80000000000000004 110.399 172.649 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.492 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.426 ' HG ' ' O ' ' A' ' 14' ' ' LEU . 30.4 tp -74.02 84.1 1.77 Allowed 'General case' 0 N--CA 1.444 -0.729 0 CA-C-O 121.449 0.642 . . . . 1.25 111.086 -178.432 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . 0.434 ' C ' ' HA ' ' A' ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -62.92 -32.69 74.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.836 0.351 . . . . 2.3599999999999999 110.887 179.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.55 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 3.7 m -136.55 -87.39 0.32 Allowed 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.681 -0.408 . . . . 0.29999999999999999 111.896 178.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.611 HD12 ' HA ' ' A' ' 2' ' ' DBB . 0.5 OUTLIER -65.24 -28.96 45.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 115.205 -0.907 . . . . 2.4300000000000002 111.105 -169.361 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . 0.442 ' N ' HG21 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.524 ' HA ' ' C ' ' A' ' 2' ' ' DBB . 40.1 t . . . . . 0 N--CA 1.481 1.123 0 N-CA-C 111.305 0.113 . . . . 3.6499999999999999 111.305 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.524 ' C ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.404 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 12.0 t80 -76.81 98.91 4.98 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.007 -0.542 . . . . 1.24 109.565 174.33 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . 0.641 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.5 mp -113.9 -43.65 0.07 OUTLIER Pre-proline 0 CA--C 1.541 0.632 0 N-CA-C 113.656 0.984 . . . . 3.1000000000000001 113.656 -172.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.68 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 51.2 Cg_exo -61.08 146.1 98.09 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.18 1.92 . . . . 2.4199999999999999 113.283 -173.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.443 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -76.28 75.11 1.61 Allowed Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.535 -0.757 . . . . 4.79 113.004 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -119.31 75.98 0.3 Allowed Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 110.421 -1.072 . . . . 5.4800000000000004 110.421 174.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.51 39.5 5.3 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 110.518 -1.033 . . . . 4.0899999999999999 110.518 -171.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.443 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 93.73 -83.28 1.03 Allowed Glycine 0 N--CA 1.444 -0.819 0 N-CA-C 110.455 -1.058 . . . . 1.76 110.455 -172.304 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.2 m -132.84 149.33 31.79 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.814 0 CA-C-O 121.822 0.82 . . . . 1.25 110.987 173.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.68 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -61.04 148.15 41.23 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 113.211 -1.813 . . . . 0.80000000000000004 109.451 168.811 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.474 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 46.0 tp -73.56 86.54 1.59 Allowed 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.318 0.58 . . . . 1.25 110.95 -178.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -59.69 -36.41 76.45 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.451 -0.34 . . . . 2.3599999999999999 110.659 178.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.474 ' HB2' ' HA ' ' A' ' 13' ' ' DBB . 3.4 m -134.58 -85.31 0.41 Allowed 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 112.123 0.416 . . . . 0.29999999999999999 112.123 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.439 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER -63.75 -30.51 50.09 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 115.431 -0.804 . . . . 2.4300000000000002 111.582 -168.691 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.504 ' HB3' ' HA ' ' A' ' 2' ' ' DBB . 1.9 t . . . . . 0 N--CA 1.478 0.964 0 N-CA-C 109.397 -0.594 . . . . 3.6499999999999999 109.397 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.504 ' HA ' ' HB3' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.784 ' HD2' ' HB3' ' A' ' 18' ' ' CYS . 22.9 t80 -64.68 111.12 2.61 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.883 -0.598 . . . . 1.24 110.255 176.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . 0.444 ' C ' HD21 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.553 ' HG ' ' CD ' ' A' ' 6' ' ' PRO . 1.1 pt? -178.3 -36.87 0.0 OUTLIER Pre-proline 0 CA--C 1.546 0.796 0 N-CA-C 112.681 0.623 . . . . 3.1000000000000001 112.681 178.394 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.553 ' CD ' ' HG ' ' A' ' 5' ' ' LEU . 3.3 Cg_endo -91.97 -159.02 0.07 OUTLIER 'Trans proline' 0 C--N 1.366 1.462 0 C-N-CA 122.222 1.948 . . . . 2.4199999999999999 112.405 -175.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.43 38.76 1.42 Allowed Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 121.035 -0.603 . . . . 4.79 112.465 -177.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.17 -92.51 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.909 -0.663 . . . . 5.4800000000000004 111.893 179.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -81.74 80.98 1.7 Allowed Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 110.738 -0.945 . . . . 4.0899999999999999 110.738 173.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.71 -84.49 0.66 Allowed Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.273 -0.731 . . . . 1.76 111.273 -171.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.84 -88.48 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 120.941 0.401 . . . . 1.25 110.535 173.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 1.5 t -173.84 81.23 0.04 OUTLIER 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 107.74 -1.208 . . . . 0.80000000000000004 107.74 -174.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.598 ' O ' ' HB ' ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 52.9 tp -73.96 66.77 1.2 Allowed 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 121.64 0.733 . . . . 1.25 109.654 177.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -59.72 -32.59 70.68 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.382 0.61 . . . . 2.3599999999999999 109.617 174.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.784 ' HB3' ' HD2' ' A' ' 3' ' ' PHE . 1.4 m -132.79 -69.32 0.57 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.54 -0.755 . . . . 0.29999999999999999 110.686 179.151 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.598 ' HB ' ' O ' ' A' ' 13' ' ' DBB . 44.2 mm -103.77 -77.33 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 CA-C-N 114.04 -1.436 . . . . 2.4300000000000002 110.996 -169.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.535 ' HB3' ' HA ' ' A' ' 2' ' ' DBB . 2.0 t . . . . . 0 N--CA 1.476 0.848 0 N-CA-C 109.223 -0.658 . . . . 3.6499999999999999 109.223 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.535 ' HA ' ' HB3' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -67.28 107.09 2.25 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.066 -0.515 . . . . 1.24 110.616 178.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . 0.61 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.568 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 1.0 OUTLIER -74.11 -35.0 2.18 Favored Pre-proline 0 CA--C 1.55 0.959 0 N-CA-C 114.589 1.329 . . . . 3.1000000000000001 114.589 -174.917 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.96 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 3.6 Cg_exo -78.56 -168.69 0.65 Allowed 'Trans proline' 0 C--N 1.361 1.193 0 C-N-CA 122.154 1.903 . . . . 2.4199999999999999 111.775 -177.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.47 ' HA2' ' HA ' ' A' ' 11' ' ' VAL . . . -112.33 -91.2 1.97 Allowed Glycine 0 N--CA 1.442 -0.922 0 C-N-CA 120.465 -0.874 . . . . 4.79 112.586 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.24 38.51 96.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.959 -0.639 . . . . 5.4800000000000004 112.078 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.72 36.72 1.37 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.939 -0.648 . . . . 4.0899999999999999 111.483 -175.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.415 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 114.35 -88.96 0.49 Allowed Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 111.319 -0.712 . . . . 1.76 111.319 -175.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.619 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 3.1 m -149.72 150.09 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.867 0 CA-C-O 121.745 0.783 . . . . 1.25 110.199 175.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.96 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -64.95 144.52 57.23 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 113.787 -1.551 . . . . 0.80000000000000004 109.927 171.746 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.597 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.4 ' HB2' ' O ' ' A' ' 11' ' ' VAL . 40.9 tp -71.74 89.42 1.03 Allowed 'General case' 0 N--CA 1.443 -0.789 0 CA-C-O 121.445 0.641 . . . . 1.25 111.797 -174.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . 0.585 ' H ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 21.1 tp10 -59.78 -40.23 87.55 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 116.285 -0.416 . . . . 2.3599999999999999 110.348 177.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.402 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 7.7 m -131.77 -82.96 0.51 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.126 0.417 . . . . 0.29999999999999999 112.126 176.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.597 HG12 ' O ' ' A' ' 13' ' ' DBB . 28.6 pt -61.21 -27.38 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 112.674 0.62 . . . . 2.4300000000000002 112.674 -167.403 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . 0.521 ' HB2' ' C ' ' A' ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.545 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 40.5 t . . . . . 0 N--CA 1.479 0.995 0 CA-C-O 119.874 -0.108 . . . . 3.6499999999999999 110.873 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.545 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.557 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 10.8 t80 -72.46 110.29 6.76 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.522 -0.548 . . . . 1.24 109.522 175.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . 0.704 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.476 ' N ' ' HD3' ' A' ' 6' ' ' PRO . 3.7 pp -69.11 -28.21 1.52 Allowed Pre-proline 0 CA--C 1.552 1.035 0 N-CA-C 115.667 1.728 . . . . 3.1000000000000001 115.667 -172.4 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.974 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 3.9 Cg_exo -83.74 158.18 14.03 Favored 'Trans proline' 0 C--N 1.36 1.167 0 C-N-CA 121.897 1.731 . . . . 2.4199999999999999 112.331 -176.712 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -109.73 73.53 0.21 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.92 -0.657 . . . . 4.79 112.563 -177.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -112.78 94.9 0.75 Allowed Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 111.301 -0.72 . . . . 5.4800000000000004 111.301 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 80.16 36.68 23.79 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 110.733 -0.947 . . . . 4.0899999999999999 110.733 -171.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.412 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 108.16 -93.1 0.78 Allowed Glycine 0 N--CA 1.443 -0.838 0 N-CA-C 111.082 -0.807 . . . . 1.76 111.082 -175.106 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 8.5 m -146.94 154.31 12.0 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.925 0 CA-C-O 121.707 0.765 . . . . 1.25 110.26 174.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.974 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -71.66 147.49 47.43 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 113.997 -1.456 . . . . 0.80000000000000004 109.358 171.165 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.482 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 55.1 tp -74.44 83.2 1.96 Allowed 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 121.246 0.546 . . . . 1.25 111.01 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -64.21 -34.02 77.13 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.676 0.274 . . . . 2.3599999999999999 111.098 -179.215 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.557 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 3.1 m -133.75 -86.21 0.43 Allowed 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.28 -0.568 . . . . 0.29999999999999999 112.498 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.452 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER -63.46 -30.18 49.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 CA-C-N 115.045 -0.98 . . . . 2.4300000000000002 111.879 -167.194 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . 0.446 ' N ' HG21 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.458 ' HB3' ' HA ' ' A' ' 2' ' ' DBB . 1.8 t . . . . . 0 N--CA 1.476 0.843 0 CA-C-O 118.877 -0.582 . . . . 3.6499999999999999 109.568 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.458 ' HA ' ' HB3' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.551 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 3.4 t80 -68.14 93.77 0.46 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.174 0.512 . . . . 1.24 110.043 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.513 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 9.9 mp -58.86 -53.94 61.39 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 113.163 0.801 . . . . 3.1000000000000001 113.163 -172.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.647 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 52.9 Cg_exo -55.87 146.12 69.35 Favored 'Trans proline' 0 C--N 1.358 1.06 0 C-N-CA 122.144 1.896 . . . . 2.4199999999999999 112.872 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -127.39 97.73 0.48 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.086 -0.578 . . . . 4.79 112.749 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -179.81 -152.22 10.61 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.885 -0.674 . . . . 5.4800000000000004 111.591 179.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.47 -32.28 68.02 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.079 -0.582 . . . . 4.0899999999999999 111.81 177.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -110.97 99.01 1.09 Allowed Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.499 -0.64 . . . . 1.76 111.499 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.9 m -114.8 153.75 16.26 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.75 0 CA-C-O 122.044 0.926 . . . . 1.25 112.03 -176.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.647 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -69.4 142.88 53.79 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 113.392 -1.731 . . . . 0.80000000000000004 109.563 170.919 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.425 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.404 ' O ' ' HG ' ' A' ' 14' ' ' LEU . 43.2 tp -73.85 83.84 1.68 Allowed 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.893 -0.594 . . . . 1.25 111.21 -176.855 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -61.57 -27.79 68.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.026 -0.534 . . . . 2.3599999999999999 110.576 177.265 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.551 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 4.6 m -144.52 -85.34 0.13 Allowed 'General case' 0 C--O 1.233 0.212 0 N-CA-C 112.024 0.379 . . . . 0.29999999999999999 112.024 177.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.484 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.5 OUTLIER -66.23 -28.97 45.21 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 CA-C-N 114.638 -1.164 . . . . 2.4300000000000002 112.386 -166.661 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . 0.481 ' N ' HG21 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.566 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 0.6 OUTLIER . . . . . 0 N--CA 1.48 1.058 0 CA-C-O 119.213 -0.422 . . . . 3.6499999999999999 109.879 . . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.566 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.559 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 4.9 t80 -67.74 111.68 4.4 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.669 -0.696 . . . . 1.24 109.24 173.678 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . 0.732 ' HB2' ' C ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.954 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 85.2 mt -137.1 -68.18 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.411 0 C-N-CA 121.317 -0.153 . . . . 3.1000000000000001 111.123 175.017 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.954 ' HD3' ' HB2' ' A' ' 5' ' ' LEU . 27.4 Cg_exo -63.46 167.07 13.78 Favored 'Trans proline' 0 C--N 1.356 0.963 0 C-N-CA 122.367 2.045 . . . . 2.4199999999999999 112.381 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -107.53 -25.08 6.15 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.91 -0.662 . . . . 4.79 112.399 -179.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -124.19 149.74 16.95 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.55 -0.833 . . . . 5.4800000000000004 112.384 179.389 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 66.88 -128.69 29.25 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 121.078 -0.582 . . . . 4.0899999999999999 112.228 179.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.423 ' O ' ' HG2' ' A' ' 6' ' ' PRO . . . -66.96 93.66 0.22 Allowed Glycine 0 N--CA 1.449 -0.452 0 N-CA-C 111.367 -0.693 . . . . 1.76 111.367 176.743 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.701 ' O ' ' HB3' ' A' ' 12' ' ' CYS . 2.2 m -88.57 -16.81 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.846 0 N-CA-C 113.186 0.809 . . . . 1.25 113.186 -171.513 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.732 ' C ' ' HB2' ' A' ' 4' ' ' DBB . 1.7 t 78.87 120.41 0.05 Allowed 'General case' 0 C--N 1.322 -0.594 0 O-C-N 124.232 0.958 . . . . 0.80000000000000004 108.809 -173.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 39.4 tp -73.75 93.02 2.06 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-O 121.444 0.64 . . . . 1.25 111.212 -177.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . 0.472 ' H ' HG23 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.6 tp10 -59.77 -31.73 69.93 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 115.542 -0.754 . . . . 2.3599999999999999 110.603 176.288 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.559 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 7.8 m -142.91 -82.03 0.19 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.006 0.431 . . . . 0.29999999999999999 111.829 177.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.472 HG23 ' H ' ' A' ' 15' ' ' DBB . 0.2 OUTLIER -66.95 -29.33 45.91 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-N 114.492 -1.231 . . . . 2.4300000000000002 111.678 -167.398 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.498 ' HB3' ' HA ' ' A' ' 2' ' ' DBB . 3.1 t . . . . . 0 N--CA 1.477 0.882 0 N-CA-C 108.747 -0.834 . . . . 3.6499999999999999 108.747 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.498 ' HA ' ' HB3' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.851 ' HD2' ' HB3' ' A' ' 18' ' ' CYS . 18.1 t80 -71.73 120.97 18.08 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.697 -0.853 . . . . 1.24 108.697 170.69 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.464 ' HA ' HD21 ' A' ' 5' ' ' LEU . 73.7 mt -67.72 -55.97 12.96 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 120.774 -0.37 . . . . 3.1000000000000001 111.541 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.712 ' HG2' ' HA ' ' A' ' 11' ' ' VAL . 36.3 Cg_endo -65.67 154.9 71.8 Favored 'Trans proline' 0 C--N 1.354 0.821 0 C-N-CA 121.806 1.671 . . . . 2.4199999999999999 111.992 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -114.85 -27.46 3.23 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.791 -0.718 . . . . 4.79 112.12 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.17 153.03 17.0 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.811 -0.709 . . . . 5.4800000000000004 112.179 178.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 72.98 -141.51 30.43 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.038 -0.601 . . . . 4.0899999999999999 112.561 179.567 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -69.33 90.11 0.28 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 121.407 -0.425 . . . . 1.76 112.249 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.712 ' HA ' ' HG2' ' A' ' 6' ' ' PRO . 35.7 m -95.84 160.74 2.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.93 0.872 . . . . 1.25 112.178 -175.546 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -70.06 93.12 0.78 Allowed 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 113.247 -1.797 . . . . 0.80000000000000004 110.061 175.315 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.66 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 39.4 tp -73.13 92.18 1.69 Allowed 'General case' 0 N--CA 1.444 -0.765 0 CA-C-O 121.233 0.539 . . . . 1.25 111.649 -177.282 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . 0.503 ' H ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 73.9 tt0 -59.59 -34.17 72.38 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.972 -0.558 . . . . 2.3599999999999999 110.666 177.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.851 ' HB3' ' HD2' ' A' ' 3' ' ' PHE . 10.0 m -136.86 -84.71 0.34 Allowed 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 111.843 0.312 . . . . 0.29999999999999999 111.843 176.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.66 HG12 ' O ' ' A' ' 13' ' ' DBB . 31.4 pt -64.1 -27.62 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 CA-C-N 115.738 -0.665 . . . . 2.4300000000000002 112.072 -168.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . 0.4 ' HA ' ' C ' ' A' ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.711 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 0.7 OUTLIER . . . . . 0 N--CA 1.477 0.907 0 N-CA-C 109.675 -0.491 . . . . 3.6499999999999999 109.675 . . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.711 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -65.78 103.43 0.9 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.994 -0.548 . . . . 1.24 110.959 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.411 ' HA ' HD21 ' A' ' 5' ' ' LEU . 96.8 mt -59.71 -54.83 51.91 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 112.983 0.734 . . . . 3.1000000000000001 112.983 -173.548 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.454 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 29.1 Cg_endo -63.78 150.88 87.42 Favored 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 121.856 1.704 . . . . 2.4199999999999999 112.333 -178.695 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.484 ' HA2' HG11 ' A' ' 11' ' ' VAL . . . -150.2 50.47 0.54 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.951 -0.642 . . . . 4.79 112.28 -177.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.24 34.82 3.55 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.775 -0.726 . . . . 5.4800000000000004 112.405 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.4 -89.48 0.49 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.681 -0.771 . . . . 4.0899999999999999 111.852 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.45 89.26 0.72 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.788 -0.72 . . . . 1.76 111.304 174.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.484 HG11 ' HA2' ' A' ' 7' ' ' GLY . 30.5 m -89.41 162.44 2.53 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.797 0 CA-C-O 122.205 1.002 . . . . 1.25 111.809 -174.125 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.454 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -72.86 96.99 2.17 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-N 113.524 -1.671 . . . . 0.80000000000000004 109.235 171.967 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.639 ' O ' ' HB ' ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 48.0 tp -73.79 74.78 1.59 Allowed 'General case' 0 N--CA 1.438 -1.031 0 CA-C-O 121.435 0.636 . . . . 1.25 109.717 178.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 -59.4 -37.09 77.11 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.776 -0.647 . . . . 2.3599999999999999 109.678 175.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.496 ' HB2' ' HA ' ' A' ' 13' ' ' DBB . 1.5 m -129.23 -86.34 0.55 Allowed 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.739 -0.664 . . . . 0.29999999999999999 110.342 175.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.639 ' HB ' ' O ' ' A' ' 13' ' ' DBB . 28.4 mm -68.12 -77.54 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-N 114.702 -1.135 . . . . 2.4300000000000002 111.558 -175.112 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.525 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 40.4 t . . . . . 0 N--CA 1.475 0.806 0 CA-C-O 119.992 -0.052 . . . . 3.6499999999999999 111.066 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.525 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.492 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 13.3 t80 -68.46 108.41 3.27 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.703 -0.681 . . . . 1.24 110.084 177.008 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . 0.404 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.578 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 7.9 mp -60.56 -53.28 66.1 Favored Pre-proline 0 N--CA 1.467 0.409 0 N-CA-C 112.53 0.567 . . . . 3.1000000000000001 112.53 -174.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.705 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 14.8 Cg_exo -68.7 92.58 0.43 Allowed 'Trans proline' 0 C--N 1.355 0.921 0 C-N-CA 122.074 1.849 . . . . 2.4199999999999999 111.64 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.758 ' HA2' HG13 ' A' ' 11' ' ' VAL . . . -103.07 83.88 0.45 Allowed Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.81 -0.709 . . . . 4.79 112.119 -177.404 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -170.87 86.07 0.08 OUTLIER Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 111.466 -0.654 . . . . 5.4800000000000004 111.466 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 70.86 -90.6 0.41 Allowed Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 111.456 -0.658 . . . . 4.0899999999999999 111.456 -175.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.41 99.96 0.77 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.858 -0.687 . . . . 1.76 111.425 173.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.758 HG13 ' HA2' ' A' ' 7' ' ' GLY . 33.9 m -113.64 152.66 15.3 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.702 0 CA-C-O 121.995 0.902 . . . . 1.25 111.883 -175.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.705 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -78.2 136.48 37.81 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 113.294 -1.776 . . . . 0.80000000000000004 108.866 169.791 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 36.8 tp -72.4 91.17 1.34 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.398 0.618 . . . . 1.25 111.784 -174.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . 0.414 ' N ' ' HB2' ' A' ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -59.32 -35.66 74.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.817 -0.629 . . . . 2.3599999999999999 109.982 176.025 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.492 ' HB3' ' HB3' ' A' ' 3' ' ' PHE . 34.6 m -134.9 -87.82 0.37 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.332 -0.394 . . . . 0.29999999999999999 111.569 175.666 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.458 HG21 ' N ' ' A' ' 20' ' ' TEE . 4.1 tt -55.91 -31.09 29.59 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-N 115.212 -0.904 . . . . 2.4300000000000002 112.989 -170.407 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . 0.458 ' N ' HG21 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.55 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 42.4 t . . . . . 0 N--CA 1.478 0.952 0 CA-C-O 120.071 -0.014 . . . . 3.6499999999999999 110.972 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.55 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.818 ' HD2' ' HB3' ' A' ' 18' ' ' CYS . 16.3 t80 -67.81 110.86 3.99 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.853 -0.612 . . . . 1.24 109.841 177.291 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.462 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 95.7 mt -71.64 -53.8 7.07 Favored Pre-proline 0 CA--C 1.537 0.474 0 N-CA-C 112.379 0.511 . . . . 3.1000000000000001 112.379 -176.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HD2' ' N ' ' A' ' 5' ' ' LEU . 20.3 Cg_endo -61.2 144.04 98.75 Favored 'Trans proline' 0 C--N 1.356 0.924 0 C-N-CA 122.067 1.844 . . . . 2.4199999999999999 112.244 -179.258 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -129.18 91.36 0.32 Allowed Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.034 -0.603 . . . . 4.79 112.437 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 175.96 -155.87 20.36 Favored Glycine 0 N--CA 1.449 -0.496 0 N-CA-C 111.276 -0.729 . . . . 5.4800000000000004 111.276 179.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.11 93.8 0.78 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.832 -0.699 . . . . 4.0899999999999999 111.75 177.052 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.2 77.96 0.79 Allowed Glycine 0 N--CA 1.444 -0.801 0 N-CA-C 111.011 -0.835 . . . . 1.76 111.011 -175.405 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 21.8 m -109.1 167.02 4.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 122.052 0.929 . . . . 1.25 112.339 -175.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -67.2 138.88 57.3 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 112.961 -1.927 . . . . 0.80000000000000004 109.346 171.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.445 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 32.8 tp -72.68 94.49 1.75 Allowed 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 115.992 -0.549 . . . . 1.25 111.632 -176.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -59.86 -32.37 70.64 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.761 -0.654 . . . . 2.3599999999999999 110.462 176.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.818 ' HB3' ' HD2' ' A' ' 3' ' ' PHE . 14.4 m -143.4 -85.72 0.14 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.288 -0.414 . . . . 0.29999999999999999 111.814 179.116 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.568 HG21 ' N ' ' A' ' 20' ' ' TEE . 0.2 OUTLIER -64.97 -31.22 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 CA-C-N 114.981 -1.009 . . . . 2.4300000000000002 111.188 -168.307 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . 0.568 ' N ' HG21 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.52 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 43.4 t . . . . . 0 N--CA 1.478 0.967 0 CA-C-O 119.825 -0.131 . . . . 3.6499999999999999 110.729 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.52 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.726 ' HD2' ' HB3' ' A' ' 18' ' ' CYS . 48.6 t80 -63.1 106.8 0.91 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.629 -0.714 . . . . 1.24 110.223 175.049 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.444 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 97.8 mt -67.74 -53.6 20.86 Favored Pre-proline 0 CA--C 1.538 0.513 0 N-CA-C 111.866 0.321 . . . . 3.1000000000000001 111.866 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.444 ' HD2' ' N ' ' A' ' 5' ' ' LEU . 34.5 Cg_endo -65.26 151.45 85.31 Favored 'Trans proline' 0 C--N 1.356 0.93 0 C-N-CA 121.978 1.785 . . . . 2.4199999999999999 112.455 -179.696 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -127.41 29.92 4.17 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.046 -0.597 . . . . 4.79 112.287 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -116.27 -136.48 5.85 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.024 -0.608 . . . . 5.4800000000000004 112.345 -179.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -71.05 -85.01 0.18 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.149 -0.548 . . . . 4.0899999999999999 112.482 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.64 92.7 0.44 Allowed Glycine 0 N--CA 1.453 -0.225 0 C-N-CA 121.164 -0.541 . . . . 1.76 112.005 178.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.405 ' HA ' ' HG2' ' A' ' 6' ' ' PRO . 19.2 m -107.05 -177.19 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.628 0 CA-C-O 122.146 0.974 . . . . 1.25 112.242 -175.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.89 142.11 29.94 Favored 'General case' 0 N--CA 1.435 -1.211 0 CA-C-N 113.46 -1.7 . . . . 0.80000000000000004 109.344 176.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . 0.686 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 29.8 tp -72.64 87.34 1.23 Allowed 'General case' 0 N--CA 1.445 -0.712 0 CA-C-O 121.193 0.521 . . . . 1.25 111.356 -177.058 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -62.77 -30.97 71.85 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.35 -0.386 . . . . 2.3599999999999999 110.792 179.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.726 ' HB3' ' HD2' ' A' ' 3' ' ' PHE . 4.8 m -138.67 -83.88 0.28 Allowed 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 112.175 0.435 . . . . 0.29999999999999999 112.175 177.311 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.686 HG12 ' O ' ' A' ' 13' ' ' DBB . 21.5 pt -67.16 -29.42 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 115.606 -0.725 . . . . 2.4300000000000002 111.969 -167.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 45.7 t . . . . . 0 N--CA 1.477 0.902 0 CA-C-O 119.943 -0.075 . . . . 3.6499999999999999 110.941 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' DBB . . . . . 0.587 ' HA ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.44 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 31.1 t80 -68.69 102.45 1.51 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.77 -0.65 . . . . 1.24 110.372 178.008 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.423 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 4.3 mm? -61.41 -58.17 20.43 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 118.112 0.415 . . . . 3.1000000000000001 110.855 179.073 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.663 ' HB2' HG13 ' A' ' 11' ' ' VAL . 76.5 Cg_endo -75.11 149.72 36.66 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 121.415 1.41 . . . . 2.4199999999999999 111.133 174.081 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -133.79 28.49 3.22 Favored Glycine 0 CA--C 1.518 0.222 0 C-N-CA 120.64 -0.791 . . . . 4.79 112.928 -177.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.87 -90.31 2.16 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.835 -0.698 . . . . 5.4800000000000004 113.021 -178.098 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.8 -94.1 2.24 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.735 -0.745 . . . . 4.0899999999999999 112.534 -177.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.505 ' HA2' HD23 ' A' ' 14' ' ' LEU . . . -70.94 86.31 0.38 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 121.022 -0.609 . . . . 1.76 111.597 177.224 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.663 HG13 ' HB2' ' A' ' 6' ' ' PRO . 34.7 m -120.96 176.01 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.706 0 CA-C-O 122.096 0.951 . . . . 1.25 112.614 -171.379 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -69.42 132.29 46.11 Favored 'General case' 0 N--CA 1.432 -1.331 0 CA-C-N 112.785 -2.007 . . . . 0.80000000000000004 109.167 170.316 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.505 HD23 ' HA2' ' A' ' 10' ' ' GLY . 36.6 tp -74.1 87.25 1.89 Allowed 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 121.323 0.582 . . . . 1.25 111.144 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' DBB . . . . . 0.536 ' H ' HG23 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -60.45 -29.07 68.79 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.266 -0.424 . . . . 2.3599999999999999 110.33 177.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.493 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.5 m -143.79 -82.18 0.17 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.313 -0.403 . . . . 0.29999999999999999 111.737 177.24 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.587 HG12 ' HA ' ' A' ' 2' ' ' DBB . 0.1 OUTLIER -63.78 -32.2 56.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 CA-C-N 115.324 -0.853 . . . . 2.4300000000000002 111.719 -167.508 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' TEE . . . . . 0.445 ' N ' HG21 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.76 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 4.3 pp . . . . . 0 CA--C 1.548 0.872 0 N-CA-C 114.269 1.211 . . . . 2.4500000000000002 114.269 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.76 ' HD3' ' HG ' ' A' ' 5' ' ' LEU . 28.4 Cg_exo -63.51 157.03 53.15 Favored 'Trans proline' 0 C--N 1.361 1.233 0 C-N-CA 121.84 1.694 . . . . 2.0099999999999998 112.806 -178.434 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -123.13 95.18 0.53 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 121.21 -0.519 . . . . 4.79 112.036 178.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 179.87 -152.86 11.29 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.895 -0.669 . . . . 4.7800000000000002 112.078 -179.086 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -90.93 -35.82 7.0 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.782 -0.723 . . . . 3.9500000000000002 111.678 178.235 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.1 87.67 0.85 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 110.944 -0.862 . . . . 1.3400000000000001 110.944 175.471 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.615 HG12 ' HB2' ' A' ' 6' ' ' PRO . 23.8 m -123.99 163.22 23.99 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.638 0 CA-C-O 121.966 0.888 . . . . 1.1100000000000001 112.24 -173.568 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.312 -1.054 0 CA-C-N 113.379 -1.737 . . . . 0.54000000000000004 109.957 173.209 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.401 ' OE1' ' HA ' ' A' ' 17' ' ' GLU . 4.3 tp10 . . . . . 0 N--CA 1.452 -0.342 0 CA-C-O 120.698 0.285 . . . . 2.3599999999999999 110.86 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 8.1 m -138.37 -83.89 0.29 Allowed 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.103 0.408 . . . . 0.29999999999999999 112.103 178.355 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 29.9 pt . . . . . 0 C--N 1.341 0.234 0 CA-C-N 115.819 -0.628 . . . . 1.8799999999999999 112.076 -167.655 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.794 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 3.4 pp . . . . . 0 CA--C 1.547 0.837 0 N-CA-C 113.175 0.805 . . . . 2.4500000000000002 113.175 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.794 ' HD3' ' HG ' ' A' ' 5' ' ' LEU . 68.6 Cg_endo -96.27 -159.97 0.06 OUTLIER 'Trans proline' 0 C--N 1.361 1.225 0 C-N-CA 121.867 1.711 . . . . 2.0099999999999998 112.441 -178.163 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -112.49 -86.96 1.62 Allowed Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.637 -0.792 . . . . 4.79 111.991 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 63.69 37.32 94.55 Favored Glycine 0 N--CA 1.452 -0.269 0 N-CA-C 111.394 -0.682 . . . . 4.7800000000000002 111.394 -177.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.05 -79.55 0.36 Allowed Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 110.899 -0.88 . . . . 3.9500000000000002 110.899 -172.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.79 -77.01 0.46 Allowed Glycine 0 N--CA 1.442 -0.916 0 N-CA-C 110.801 -0.92 . . . . 1.3400000000000001 110.801 172.759 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 10.2 m -149.49 173.55 1.35 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.747 0 CA-C-O 121.561 0.696 . . . . 1.1100000000000001 110.504 175.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.435 ' CB ' ' HD2' ' A' ' 6' ' ' PRO . 1.0 OUTLIER . . . . . 0 C--N 1.303 -1.434 0 CA-C-N 113.571 -1.649 . . . . 0.54000000000000004 108.65 168.273 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 43.9 tp10 . . . . . 0 N--CA 1.454 -0.243 0 CA-C-O 120.791 0.329 . . . . 2.3599999999999999 110.836 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.445 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 7.6 m -141.74 -82.85 0.21 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.101 0.477 . . . . 0.29999999999999999 111.693 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.445 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER . . . . . 0 N--CA 1.452 -0.355 0 CA-C-N 114.771 -1.104 . . . . 1.8799999999999999 111.179 -168.787 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.674 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 4.9 mp . . . . . 0 CA--C 1.54 0.579 0 N-CA-C 112.808 0.67 . . . . 2.4500000000000002 112.808 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.674 ' HD3' ' HB2' ' A' ' 5' ' ' LEU . 5.0 Cg_exo -79.76 164.25 23.18 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 122.64 2.227 . . . . 2.0099999999999998 112.496 -174.399 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.591 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -70.98 -93.73 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.854 -0.612 . . . . 4.79 112.238 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.8 35.79 90.69 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 121.158 -0.544 . . . . 4.7800000000000002 112.578 178.632 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 108.43 34.29 2.72 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.742 -0.742 . . . . 3.9500000000000002 111.467 -176.282 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.591 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 116.72 -92.4 0.56 Allowed Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 111.446 -0.661 . . . . 1.3400000000000001 111.446 -176.441 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 6.5 m -150.55 154.11 9.26 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.723 0 CA-C-O 121.615 0.722 . . . . 1.1100000000000001 110.188 176.387 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.575 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.305 -1.365 0 CA-C-N 114.115 -1.402 . . . . 0.54000000000000004 109.342 172.104 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 13.8 tp10 . . . . . 0 N--CA 1.453 -0.285 0 CA-C-O 120.918 0.389 . . . . 2.3599999999999999 110.616 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.473 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 6.0 m -131.75 -86.56 0.48 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.336 -0.393 . . . . 0.29999999999999999 111.873 -177.635 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.473 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.3 OUTLIER . . . . . 0 CA--C 1.533 0.316 0 CA-C-N 115.036 -0.984 . . . . 1.8799999999999999 111.348 -168.596 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.634 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 1.5 pt? . . . . . 0 CA--C 1.542 0.661 0 N-CA-C 114.134 1.161 . . . . 2.4500000000000002 114.134 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.663 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 20.8 Cg_exo -68.72 151.51 74.59 Favored 'Trans proline' 0 C--N 1.358 1.066 0 C-N-CA 121.647 1.564 . . . . 2.0099999999999998 112.23 -177.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.43 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -110.96 54.1 0.55 Allowed Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.761 -0.654 . . . . 4.79 112.312 -178.763 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -112.34 80.81 0.28 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.746 -0.74 . . . . 4.7800000000000002 111.278 177.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.1 28.51 5.82 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.159 -0.776 . . . . 3.9500000000000002 111.159 -175.203 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.43 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 108.24 -113.57 3.89 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.181 -0.768 . . . . 1.3400000000000001 111.181 -176.046 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.8 m -132.26 156.14 42.15 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.77 0 CA-C-O 121.745 0.783 . . . . 1.1100000000000001 110.458 173.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.663 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.304 -1.381 0 CA-C-N 113.812 -1.54 . . . . 0.54000000000000004 110.323 174.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 . . . . . 0 N--CA 1.452 -0.356 0 CA-C-O 120.485 0.183 . . . . 2.3599999999999999 110.523 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.413 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 4.9 m -136.67 -84.93 0.34 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.94 -0.304 . . . . 0.29999999999999999 111.769 176.378 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.413 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 24.5 pt . . . . . 0 N--CA 1.451 -0.375 0 CA-C-N 115.773 -0.649 . . . . 1.8799999999999999 111.993 -167.614 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.486 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 6.5 mp . . . . . 0 CA--C 1.544 0.732 0 N-CA-C 114.936 1.458 . . . . 2.4500000000000002 114.936 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.738 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 21.6 Cg_endo -67.59 152.64 77.97 Favored 'Trans proline' 0 C--N 1.356 0.953 0 C-N-CA 121.851 1.701 . . . . 2.0099999999999998 112.823 -173.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.471 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -119.15 87.25 0.41 Allowed Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.804 -0.712 . . . . 4.79 112.851 -177.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -113.97 -43.34 0.8 Allowed Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.943 -0.863 . . . . 4.7800000000000002 110.943 175.619 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -119.35 36.97 3.31 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 109.893 -1.283 . . . . 3.9500000000000002 109.893 172.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.471 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 112.24 -89.09 0.52 Allowed Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 110.507 -1.037 . . . . 1.3400000000000001 110.507 -172.126 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.654 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -151.35 150.4 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.956 0 CA-C-O 121.486 0.66 . . . . 1.1100000000000001 110.088 173.112 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.738 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.303 -1.431 0 CA-C-N 114.127 -1.397 . . . . 0.54000000000000004 110.399 172.649 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 . . . . . 0 N--CA 1.454 -0.254 0 CA-C-O 120.836 0.351 . . . . 2.3599999999999999 110.887 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.422 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.7 m -136.55 -87.39 0.32 Allowed 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.681 -0.408 . . . . 0.29999999999999999 111.896 178.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.422 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.5 OUTLIER . . . . . 0 CA--C 1.535 0.376 0 CA-C-N 115.205 -0.907 . . . . 1.8799999999999999 111.105 -169.361 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.437 HD12 ' N ' ' A' ' 5' ' ' LEU . 5.5 mp . . . . . 0 CA--C 1.541 0.632 0 N-CA-C 113.656 0.984 . . . . 2.4500000000000002 113.656 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.689 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 51.2 Cg_exo -61.08 146.1 98.09 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.18 1.92 . . . . 2.0099999999999998 113.283 -173.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -76.28 75.11 1.61 Allowed Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.535 -0.757 . . . . 4.79 113.004 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -119.31 75.98 0.3 Allowed Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 110.421 -1.072 . . . . 4.7800000000000002 110.421 174.361 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.51 39.5 5.3 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 110.518 -1.033 . . . . 3.9500000000000002 110.518 -171.519 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.455 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 93.73 -83.28 1.03 Allowed Glycine 0 N--CA 1.444 -0.819 0 N-CA-C 110.455 -1.058 . . . . 1.3400000000000001 110.455 -172.304 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.2 m -132.84 149.33 31.79 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.814 0 CA-C-O 121.822 0.82 . . . . 1.1100000000000001 110.987 173.744 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.689 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.303 -1.44 0 CA-C-N 113.211 -1.813 . . . . 0.54000000000000004 109.451 168.811 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 . . . . . 0 N--CA 1.454 -0.231 0 CA-C-O 120.776 0.322 . . . . 2.3599999999999999 110.659 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.45 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.4 m -134.58 -85.31 0.41 Allowed 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 112.123 0.416 . . . . 0.29999999999999999 112.123 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.45 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER . . . . . 0 CA--C 1.535 0.377 0 CA-C-N 115.431 -0.804 . . . . 1.8799999999999999 111.582 -168.691 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.574 ' HG ' ' CD ' ' A' ' 6' ' ' PRO . 1.1 pt? . . . . . 0 CA--C 1.546 0.796 0 N-CA-C 112.681 0.623 . . . . 2.4500000000000002 112.681 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.574 ' CD ' ' HG ' ' A' ' 5' ' ' LEU . 3.3 Cg_endo -91.97 -159.02 0.07 OUTLIER 'Trans proline' 0 C--N 1.366 1.462 0 C-N-CA 122.222 1.948 . . . . 2.0099999999999998 112.405 -175.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.43 38.76 1.42 Allowed Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 121.035 -0.603 . . . . 4.79 112.465 -177.762 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.17 -92.51 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.909 -0.663 . . . . 4.7800000000000002 111.893 179.418 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -81.74 80.98 1.7 Allowed Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 110.738 -0.945 . . . . 3.9500000000000002 110.738 173.6 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.71 -84.49 0.66 Allowed Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.273 -0.731 . . . . 1.3400000000000001 111.273 -171.493 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.608 HG23 ' H ' ' A' ' 12' ' ' CYS . 0.0 OUTLIER -128.84 -88.48 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 120.941 0.401 . . . . 1.1100000000000001 110.535 173.667 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.608 ' H ' HG23 ' A' ' 11' ' ' VAL . 1.5 t . . . . . 0 N--CA 1.441 -0.891 0 N-CA-C 107.74 -1.208 . . . . 0.54000000000000004 107.74 -174.476 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 . . . . . 0 N--CA 1.455 -0.212 0 CA-C-O 121.382 0.61 . . . . 2.3599999999999999 109.617 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 1.4 m -132.79 -69.32 0.57 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.54 -0.755 . . . . 0.29999999999999999 110.686 179.151 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 44.2 mm . . . . . 0 N--CA 1.447 -0.587 0 CA-C-N 114.04 -1.436 . . . . 1.8799999999999999 110.996 -169.741 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.562 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 1.0 OUTLIER . . . . . 0 CA--C 1.55 0.959 0 N-CA-C 114.589 1.329 . . . . 2.4500000000000002 114.589 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.986 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 3.6 Cg_exo -78.56 -168.69 0.65 Allowed 'Trans proline' 0 C--N 1.361 1.193 0 C-N-CA 122.154 1.903 . . . . 2.0099999999999998 111.775 -177.395 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.512 ' HA2' ' HA ' ' A' ' 11' ' ' VAL . . . -112.33 -91.2 1.97 Allowed Glycine 0 N--CA 1.442 -0.922 0 C-N-CA 120.465 -0.874 . . . . 4.79 112.586 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.24 38.51 96.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.959 -0.639 . . . . 4.7800000000000002 112.078 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.72 36.72 1.37 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.939 -0.648 . . . . 3.9500000000000002 111.483 -175.443 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.434 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 114.35 -88.96 0.49 Allowed Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 111.319 -0.712 . . . . 1.3400000000000001 111.319 -175.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.582 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 3.1 m -149.72 150.09 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.867 0 CA-C-O 121.745 0.783 . . . . 1.1100000000000001 110.199 175.058 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.986 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.304 -1.371 0 CA-C-N 113.787 -1.551 . . . . 0.54000000000000004 109.927 171.746 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 21.1 tp10 . . . . . 0 N--CA 1.45 -0.437 0 CA-C-O 120.691 0.281 . . . . 2.3599999999999999 110.348 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 7.7 m -131.77 -82.96 0.51 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.126 0.417 . . . . 0.29999999999999999 112.126 176.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 28.6 pt . . . . . 0 N--CA 1.455 -0.176 0 N-CA-C 112.674 0.62 . . . . 1.8799999999999999 112.674 -167.403 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.488 ' N ' ' HD3' ' A' ' 6' ' ' PRO . 3.7 pp . . . . . 0 CA--C 1.552 1.035 0 N-CA-C 115.667 1.728 . . . . 2.4500000000000002 115.667 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.981 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 3.9 Cg_exo -83.74 158.18 14.03 Favored 'Trans proline' 0 C--N 1.36 1.167 0 C-N-CA 121.897 1.731 . . . . 2.0099999999999998 112.331 -176.712 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.428 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -109.73 73.53 0.21 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.92 -0.657 . . . . 4.79 112.563 -177.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -112.78 94.9 0.75 Allowed Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 111.301 -0.72 . . . . 4.7800000000000002 111.301 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 80.16 36.68 23.79 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 110.733 -0.947 . . . . 3.9500000000000002 110.733 -171.156 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.428 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 108.16 -93.1 0.78 Allowed Glycine 0 N--CA 1.443 -0.838 0 N-CA-C 111.082 -0.807 . . . . 1.3400000000000001 111.082 -175.106 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 8.5 m -146.94 154.31 12.0 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.925 0 CA-C-O 121.707 0.765 . . . . 1.1100000000000001 110.26 174.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.981 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.302 -1.498 0 CA-C-N 113.997 -1.456 . . . . 0.54000000000000004 109.358 171.165 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 . . . . . 0 N--CA 1.453 -0.292 0 CA-C-O 120.676 0.274 . . . . 2.3599999999999999 111.098 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.414 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.1 m -133.75 -86.21 0.43 Allowed 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.28 -0.568 . . . . 0.29999999999999999 112.498 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.414 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER . . . . . 0 CA--C 1.538 0.497 0 CA-C-N 115.045 -0.98 . . . . 1.8799999999999999 111.879 -167.194 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.53 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 9.9 mp . . . . . 0 CA--C 1.538 0.489 0 N-CA-C 113.163 0.801 . . . . 2.4500000000000002 113.163 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.671 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 52.9 Cg_exo -55.87 146.12 69.35 Favored 'Trans proline' 0 C--N 1.358 1.06 0 C-N-CA 122.144 1.896 . . . . 2.0099999999999998 112.872 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -127.39 97.73 0.48 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.086 -0.578 . . . . 4.79 112.749 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -179.81 -152.22 10.61 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.885 -0.674 . . . . 4.7800000000000002 111.591 179.104 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.47 -32.28 68.02 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.079 -0.582 . . . . 3.9500000000000002 111.81 177.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -110.97 99.01 1.09 Allowed Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.499 -0.64 . . . . 1.3400000000000001 111.499 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.9 m -114.8 153.75 16.26 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.75 0 CA-C-O 122.044 0.926 . . . . 1.1100000000000001 112.03 -176.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.671 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.308 -1.213 0 CA-C-N 113.392 -1.731 . . . . 0.54000000000000004 109.563 170.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 . . . . . 0 N--CA 1.454 -0.255 0 CA-C-O 120.634 0.255 . . . . 2.3599999999999999 110.576 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.429 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 4.6 m -144.52 -85.34 0.13 Allowed 'General case' 0 C--O 1.233 0.212 0 N-CA-C 112.024 0.379 . . . . 0.29999999999999999 112.024 177.754 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.429 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.5 OUTLIER . . . . . 0 CA--C 1.537 0.469 0 CA-C-N 114.638 -1.164 . . . . 1.8799999999999999 112.386 -166.661 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.984 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 85.2 mt . . . . . 0 CA--C 1.536 0.411 0 CA-C-O 119.824 -0.131 . . . . 2.4500000000000002 111.123 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.984 ' HD3' ' HB2' ' A' ' 5' ' ' LEU . 27.4 Cg_exo -63.46 167.07 13.78 Favored 'Trans proline' 0 C--N 1.356 0.963 0 C-N-CA 122.367 2.045 . . . . 2.0099999999999998 112.381 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -107.53 -25.08 6.15 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.91 -0.662 . . . . 4.79 112.399 -179.404 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -124.19 149.74 16.95 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.55 -0.833 . . . . 4.7800000000000002 112.384 179.389 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 66.88 -128.69 29.25 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 121.078 -0.582 . . . . 3.9500000000000002 112.228 179.503 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.411 ' O ' ' HG2' ' A' ' 6' ' ' PRO . . . -66.96 93.66 0.22 Allowed Glycine 0 N--CA 1.449 -0.452 0 N-CA-C 111.367 -0.693 . . . . 1.3400000000000001 111.367 176.743 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.702 ' O ' ' HB3' ' A' ' 12' ' ' CYS . 2.2 m -88.57 -16.81 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.846 0 N-CA-C 113.186 0.809 . . . . 1.1100000000000001 113.186 -171.513 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.702 ' HB3' ' O ' ' A' ' 11' ' ' VAL . 1.7 t . . . . . 0 C--N 1.322 -0.594 0 O-C-N 124.232 0.958 . . . . 0.54000000000000004 108.809 -173.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.6 tp10 . . . . . 0 N--CA 1.451 -0.378 0 CA-C-O 120.791 0.329 . . . . 2.3599999999999999 110.603 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.428 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 7.8 m -142.91 -82.03 0.19 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.006 0.431 . . . . 0.29999999999999999 111.829 177.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.428 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.2 OUTLIER . . . . . 0 CA--C 1.534 0.348 0 CA-C-N 114.492 -1.231 . . . . 1.8799999999999999 111.678 -167.398 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.411 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 73.7 mt . . . . . 0 CA--C 1.536 0.435 0 N-CA-C 111.541 0.2 . . . . 2.4500000000000002 111.541 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.696 ' HG2' ' HA ' ' A' ' 11' ' ' VAL . 36.3 Cg_endo -65.67 154.9 71.8 Favored 'Trans proline' 0 C--N 1.354 0.821 0 C-N-CA 121.806 1.671 . . . . 2.0099999999999998 111.992 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -114.85 -27.46 3.23 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.791 -0.718 . . . . 4.79 112.12 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.17 153.03 17.0 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.811 -0.709 . . . . 4.7800000000000002 112.179 178.603 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 72.98 -141.51 30.43 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.038 -0.601 . . . . 3.9500000000000002 112.561 179.567 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -69.33 90.11 0.28 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 121.407 -0.425 . . . . 1.3400000000000001 112.249 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.696 ' HA ' ' HG2' ' A' ' 6' ' ' PRO . 35.7 m -95.84 160.74 2.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.93 0.872 . . . . 1.1100000000000001 112.178 -175.546 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.311 -1.066 0 CA-C-N 113.247 -1.797 . . . . 0.54000000000000004 110.061 175.315 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 73.9 tt0 . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 120.705 0.288 . . . . 2.3599999999999999 110.666 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 10.0 m -136.86 -84.71 0.34 Allowed 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 111.843 0.312 . . . . 0.29999999999999999 111.843 176.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 31.4 pt . . . . . 0 N--CA 1.45 -0.44 0 CA-C-N 115.738 -0.665 . . . . 1.8799999999999999 112.072 -168.582 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.4 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 96.8 mt . . . . . 0 CA--C 1.539 0.542 0 N-CA-C 112.983 0.734 . . . . 2.4500000000000002 112.983 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.478 ' HG2' ' H ' ' A' ' 12' ' ' CYS . 29.1 Cg_endo -63.78 150.88 87.42 Favored 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 121.856 1.704 . . . . 2.0099999999999998 112.333 -178.695 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.577 ' HA2' HG12 ' A' ' 11' ' ' VAL . . . -150.2 50.47 0.54 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.951 -0.642 . . . . 4.79 112.28 -177.883 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.24 34.82 3.55 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.775 -0.726 . . . . 4.7800000000000002 112.405 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.4 -89.48 0.49 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.681 -0.771 . . . . 3.9500000000000002 111.852 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.45 89.26 0.72 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.788 -0.72 . . . . 1.3400000000000001 111.304 174.115 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.577 HG12 ' HA2' ' A' ' 7' ' ' GLY . 30.5 m -89.41 162.44 2.53 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.797 0 CA-C-O 122.205 1.002 . . . . 1.1100000000000001 111.809 -174.125 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.478 ' H ' ' HG2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.432 -1.37 0 CA-C-N 113.524 -1.671 . . . . 0.54000000000000004 109.235 171.967 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 . . . . . 0 N--CA 1.454 -0.256 0 N-CA-C 109.678 -0.49 . . . . 2.3599999999999999 109.678 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.521 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 1.5 m -129.23 -86.34 0.55 Allowed 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.739 -0.664 . . . . 0.29999999999999999 110.342 175.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.521 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 28.4 mm . . . . . 0 N--CA 1.448 -0.566 0 CA-C-N 114.702 -1.135 . . . . 1.8799999999999999 111.558 -175.112 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.59 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 7.9 mp . . . . . 0 N--CA 1.467 0.409 0 N-CA-C 112.53 0.567 . . . . 2.4500000000000002 112.53 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.743 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 14.8 Cg_exo -68.7 92.58 0.43 Allowed 'Trans proline' 0 C--N 1.355 0.921 0 C-N-CA 122.074 1.849 . . . . 2.0099999999999998 111.64 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.571 ' HA2' HG12 ' A' ' 11' ' ' VAL . . . -103.07 83.88 0.45 Allowed Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.81 -0.709 . . . . 4.79 112.119 -177.404 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -170.87 86.07 0.08 OUTLIER Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 111.466 -0.654 . . . . 4.7800000000000002 111.466 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 70.86 -90.6 0.41 Allowed Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 111.456 -0.658 . . . . 3.9500000000000002 111.456 -175.783 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.41 99.96 0.77 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.858 -0.687 . . . . 1.3400000000000001 111.425 173.21 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.571 HG12 ' HA2' ' A' ' 7' ' ' GLY . 33.9 m -113.64 152.66 15.3 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.702 0 CA-C-O 121.995 0.902 . . . . 1.1100000000000001 111.883 -175.797 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.743 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.306 -1.29 0 CA-C-N 113.294 -1.776 . . . . 0.54000000000000004 108.866 169.791 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 . . . . . 0 N--CA 1.452 -0.372 0 N-CA-C 109.982 -0.377 . . . . 2.3599999999999999 109.982 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 34.6 m -134.9 -87.82 0.37 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.332 -0.394 . . . . 0.29999999999999999 111.569 175.666 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 4.1 tt . . . . . 0 CA--C 1.535 0.388 0 CA-C-N 115.212 -0.904 . . . . 1.8799999999999999 112.989 -170.407 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.47 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 95.7 mt . . . . . 0 CA--C 1.537 0.474 0 N-CA-C 112.379 0.511 . . . . 2.4500000000000002 112.379 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.47 ' HD2' ' N ' ' A' ' 5' ' ' LEU . 20.3 Cg_endo -61.2 144.04 98.75 Favored 'Trans proline' 0 C--N 1.356 0.924 0 C-N-CA 122.067 1.844 . . . . 2.0099999999999998 112.244 -179.258 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -129.18 91.36 0.32 Allowed Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.034 -0.603 . . . . 4.79 112.437 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 175.96 -155.87 20.36 Favored Glycine 0 N--CA 1.449 -0.496 0 N-CA-C 111.276 -0.729 . . . . 4.7800000000000002 111.276 179.509 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.11 93.8 0.78 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.832 -0.699 . . . . 3.9500000000000002 111.75 177.052 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.2 77.96 0.79 Allowed Glycine 0 N--CA 1.444 -0.801 0 N-CA-C 111.011 -0.835 . . . . 1.3400000000000001 111.011 -175.405 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 21.8 m -109.1 167.02 4.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 122.052 0.929 . . . . 1.1100000000000001 112.339 -175.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.309 -1.153 0 CA-C-N 112.961 -1.927 . . . . 0.54000000000000004 109.346 171.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 . . . . . 0 N--CA 1.455 -0.214 0 CA-C-O 120.872 0.368 . . . . 2.3599999999999999 110.462 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.468 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 14.4 m -143.4 -85.72 0.14 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.288 -0.414 . . . . 0.29999999999999999 111.814 179.116 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.484 HD13 ' O ' ' A' ' 19' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.452 -0.368 0 CA-C-N 114.981 -1.009 . . . . 1.8799999999999999 111.188 -168.307 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.454 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 97.8 mt . . . . . 0 CA--C 1.538 0.513 0 N-CA-C 111.866 0.321 . . . . 2.4500000000000002 111.866 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.454 ' HD2' ' N ' ' A' ' 5' ' ' LEU . 34.5 Cg_endo -65.26 151.45 85.31 Favored 'Trans proline' 0 C--N 1.356 0.93 0 C-N-CA 121.978 1.785 . . . . 2.0099999999999998 112.455 -179.696 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -127.41 29.92 4.17 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.046 -0.597 . . . . 4.79 112.287 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -116.27 -136.48 5.85 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.024 -0.608 . . . . 4.7800000000000002 112.345 -179.335 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -71.05 -85.01 0.18 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.149 -0.548 . . . . 3.9500000000000002 112.482 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.64 92.7 0.44 Allowed Glycine 0 N--CA 1.453 -0.225 0 C-N-CA 121.164 -0.541 . . . . 1.3400000000000001 112.005 178.397 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 19.2 m -107.05 -177.19 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.628 0 CA-C-O 122.146 0.974 . . . . 1.1100000000000001 112.242 -175.686 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.435 -1.211 0 CA-C-N 113.46 -1.7 . . . . 0.54000000000000004 109.344 176.669 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 . . . . . 0 CA--C 1.53 0.185 0 CA-C-O 120.815 0.34 . . . . 2.3599999999999999 110.792 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.4 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 4.8 m -138.67 -83.88 0.28 Allowed 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 112.175 0.435 . . . . 0.29999999999999999 112.175 177.311 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.4 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 21.5 pt . . . . . 0 N--CA 1.45 -0.457 0 CA-C-N 115.606 -0.725 . . . . 1.8799999999999999 111.969 -167.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.456 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 4.3 mm? . . . . . 0 CA--C 1.533 0.315 0 CA-C-O 119.816 -0.135 . . . . 2.4500000000000002 110.855 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.675 ' HB2' HG12 ' A' ' 11' ' ' VAL . 76.5 Cg_endo -75.11 149.72 36.66 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 121.415 1.41 . . . . 2.0099999999999998 111.133 174.081 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -133.79 28.49 3.22 Favored Glycine 0 CA--C 1.518 0.222 0 C-N-CA 120.64 -0.791 . . . . 4.79 112.928 -177.666 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.87 -90.31 2.16 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.835 -0.698 . . . . 4.7800000000000002 113.021 -178.098 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.8 -94.1 2.24 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.735 -0.745 . . . . 3.9500000000000002 112.534 -177.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.94 86.31 0.38 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 121.022 -0.609 . . . . 1.3400000000000001 111.597 177.224 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.675 HG12 ' HB2' ' A' ' 6' ' ' PRO . 34.7 m -120.96 176.01 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.706 0 CA-C-O 122.096 0.951 . . . . 1.1100000000000001 112.614 -171.379 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.432 -1.331 0 CA-C-N 112.785 -2.007 . . . . 0.54000000000000004 109.167 170.316 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 . . . . . 0 N--CA 1.453 -0.28 0 CA-C-O 120.776 0.322 . . . . 2.3599999999999999 110.33 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.414 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.5 m -143.79 -82.18 0.17 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.313 -0.403 . . . . 0.29999999999999999 111.737 177.24 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.488 HD13 ' O ' ' A' ' 19' ' ' ILE . 0.1 OUTLIER . . . . . 0 CA--C 1.537 0.471 0 CA-C-N 115.324 -0.853 . . . . 1.8799999999999999 111.719 -167.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.672 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 40.6 t . . . . . 0 N--CA 1.477 0.883 0 CA-C-O 119.928 -0.082 . . . . 3.1499999999999999 110.963 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.672 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.812 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 28.6 t80 -58.25 106.61 0.39 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.686 -0.688 . . . . 1.03 110.951 -179.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' DBB . . . . . 0.433 ' HB2' ' H ' ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.76 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 4.3 pp -70.48 -35.49 4.77 Favored Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 114.269 1.211 . . . . 2.4500000000000002 114.269 -173.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.76 ' HD3' ' HG ' ' A' ' 5' ' ' LEU . 28.4 Cg_exo -63.51 157.03 53.15 Favored 'Trans proline' 0 C--N 1.361 1.233 0 C-N-CA 121.84 1.694 . . . . 2.0099999999999998 112.806 -178.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -123.13 95.18 0.53 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 121.21 -0.519 . . . . 4.79 112.036 178.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 179.87 -152.86 11.29 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.895 -0.669 . . . . 4.7800000000000002 112.078 -179.086 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -90.93 -35.82 7.0 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.782 -0.723 . . . . 3.9500000000000002 111.678 178.235 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.1 87.67 0.85 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 110.944 -0.862 . . . . 1.3400000000000001 110.944 175.471 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.615 HG12 ' HB2' ' A' ' 6' ' ' PRO . 23.8 m -123.99 163.22 23.99 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.638 0 CA-C-O 121.966 0.888 . . . . 1.1100000000000001 112.24 -173.568 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -61.43 137.08 58.23 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 113.379 -1.737 . . . . 0.54000000000000004 109.957 173.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.621 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 51.9 tp -72.3 92.32 1.39 Allowed 'General case' 0 N--CA 1.444 -0.729 0 CA-C-O 121.364 0.602 . . . . 0.63 111.681 -176.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.401 ' OE1' ' HA ' ' A' ' 17' ' ' GLU . 4.3 tp10 -61.9 -32.69 73.09 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.286 -0.415 . . . . 2.3599999999999999 110.86 179.29 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.812 ' HB3' ' HB3' ' A' ' 3' ' ' PHE . 8.1 m -138.37 -83.89 0.29 Allowed 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.103 0.408 . . . . 0.29999999999999999 112.103 178.355 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.621 HG12 ' O ' ' A' ' 13' ' ' DBB . 29.9 pt -61.97 -31.68 51.95 Favored 'Isoleucine or valine' 0 C--N 1.341 0.234 0 CA-C-N 115.819 -0.628 . . . . 1.8799999999999999 112.076 -167.655 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.551 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 41.9 t . . . . . 0 N--CA 1.479 0.991 0 CA-C-O 120.305 0.098 . . . . 3.1499999999999999 111.188 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.746 ' HA ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -67.03 106.37 1.93 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.269 -0.423 . . . . 1.03 110.662 176.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.794 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 3.4 pp -175.62 -35.12 0.0 OUTLIER Pre-proline 0 CA--C 1.547 0.837 0 N-CA-C 113.175 0.805 . . . . 2.4500000000000002 113.175 175.664 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.794 ' HD3' ' HG ' ' A' ' 5' ' ' LEU . 68.6 Cg_endo -96.27 -159.97 0.06 OUTLIER 'Trans proline' 0 C--N 1.361 1.225 0 C-N-CA 121.867 1.711 . . . . 2.0099999999999998 112.441 -178.163 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -112.49 -86.96 1.62 Allowed Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.637 -0.792 . . . . 4.79 111.991 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 63.69 37.32 94.55 Favored Glycine 0 N--CA 1.452 -0.269 0 N-CA-C 111.394 -0.682 . . . . 4.7800000000000002 111.394 -177.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.05 -79.55 0.36 Allowed Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 110.899 -0.88 . . . . 3.9500000000000002 110.899 -172.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.79 -77.01 0.46 Allowed Glycine 0 N--CA 1.442 -0.916 0 N-CA-C 110.801 -0.92 . . . . 1.3400000000000001 110.801 172.759 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 10.2 m -149.49 173.55 1.35 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.747 0 CA-C-O 121.561 0.696 . . . . 1.1100000000000001 110.504 175.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.435 ' CB ' ' HD2' ' A' ' 6' ' ' PRO . 1.0 OUTLIER -72.84 132.77 43.97 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 113.571 -1.649 . . . . 0.54000000000000004 108.65 168.273 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.431 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 36.0 tp -73.28 92.35 1.78 Allowed 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.003 0.43 . . . . 0.63 111.372 -178.051 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 43.9 tp10 -59.54 -31.28 69.26 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.034 -0.53 . . . . 2.3599999999999999 110.836 177.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.445 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 7.6 m -141.74 -82.85 0.21 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.101 0.477 . . . . 0.29999999999999999 111.693 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.746 HG12 ' HA ' ' A' ' 2' ' ' DBB . 0.4 OUTLIER -69.85 -31.72 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.355 0 CA-C-N 114.771 -1.104 . . . . 1.8799999999999999 111.179 -168.787 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 41.6 t . . . . . 0 N--CA 1.476 0.846 0 CA-C-O 119.959 -0.067 . . . . 3.1499999999999999 110.869 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.573 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.445 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 14.5 t80 -70.29 111.22 5.73 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.794 -0.639 . . . . 1.03 110.604 178.281 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' DBB . . . . . 0.625 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.674 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 4.9 mp -130.79 -54.71 0.03 OUTLIER Pre-proline 0 CA--C 1.54 0.579 0 N-CA-C 112.808 0.67 . . . . 2.4500000000000002 112.808 -175.124 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.674 ' HD3' ' HB2' ' A' ' 5' ' ' LEU . 5.0 Cg_exo -79.76 164.25 23.18 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 122.64 2.227 . . . . 2.0099999999999998 112.496 -174.399 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.591 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -70.98 -93.73 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.854 -0.612 . . . . 4.79 112.238 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.8 35.79 90.69 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 121.158 -0.544 . . . . 4.7800000000000002 112.578 178.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 108.43 34.29 2.72 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.742 -0.742 . . . . 3.9500000000000002 111.467 -176.282 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.591 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 116.72 -92.4 0.56 Allowed Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 111.446 -0.661 . . . . 1.3400000000000001 111.446 -176.441 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 6.5 m -150.55 154.11 9.26 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.723 0 CA-C-O 121.615 0.722 . . . . 1.1100000000000001 110.188 176.387 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.625 ' O ' ' HA ' ' A' ' 4' ' ' DBB . 0.0 OUTLIER -65.85 136.29 55.97 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 114.115 -1.402 . . . . 0.54000000000000004 109.342 172.104 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.462 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 39.5 tp -73.0 91.47 1.57 Allowed 'General case' 0 N--CA 1.443 -0.776 0 CA-C-O 121.205 0.526 . . . . 0.63 111.265 -177.258 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 13.8 tp10 -63.24 -35.25 79.7 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.918 0.389 . . . . 2.3599999999999999 110.616 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.473 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 6.0 m -131.75 -86.56 0.48 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.336 -0.393 . . . . 0.29999999999999999 111.873 -177.635 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.473 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.3 OUTLIER -67.8 -31.15 51.0 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 CA-C-N 115.036 -0.984 . . . . 1.8799999999999999 111.348 -168.596 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.625 ' HA ' ' C ' ' A' ' 2' ' ' DBB . 44.4 t . . . . . 0 N--CA 1.48 1.064 0 N-CA-C 111.513 0.19 . . . . 3.1499999999999999 111.513 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.625 ' C ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.502 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 4.1 t80 -79.68 94.06 5.64 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.585 -0.524 . . . . 1.03 109.585 177.507 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' DBB . . . . . 0.681 ' HB2' HD23 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.681 HD23 ' HB2' ' A' ' 4' ' ' DBB . 1.5 pt? -165.68 -38.44 0.0 OUTLIER Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 114.134 1.161 . . . . 2.4500000000000002 114.134 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.663 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 20.8 Cg_exo -68.72 151.51 74.59 Favored 'Trans proline' 0 C--N 1.358 1.066 0 C-N-CA 121.647 1.564 . . . . 2.0099999999999998 112.23 -177.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.43 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -110.96 54.1 0.55 Allowed Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.761 -0.654 . . . . 4.79 112.312 -178.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -112.34 80.81 0.28 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.746 -0.74 . . . . 4.7800000000000002 111.278 177.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.1 28.51 5.82 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.159 -0.776 . . . . 3.9500000000000002 111.159 -175.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.43 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 108.24 -113.57 3.89 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.181 -0.768 . . . . 1.3400000000000001 111.181 -176.046 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.8 m -132.26 156.14 42.15 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.77 0 CA-C-O 121.745 0.783 . . . . 1.1100000000000001 110.458 173.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.663 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -67.11 99.37 0.66 Allowed 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 113.812 -1.54 . . . . 0.54000000000000004 110.323 174.969 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.648 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 42.1 tp -73.04 88.62 1.41 Allowed 'General case' 0 N--CA 1.445 -0.693 0 CA-C-O 121.215 0.531 . . . . 0.63 111.286 -178.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -61.56 -34.03 74.87 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 116.008 -0.542 . . . . 2.3599999999999999 110.523 178.595 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.502 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 4.9 m -136.67 -84.93 0.34 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.94 -0.304 . . . . 0.29999999999999999 111.769 176.378 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.648 HG12 ' O ' ' A' ' 13' ' ' DBB . 24.5 pt -63.82 -29.94 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.375 0 CA-C-N 115.773 -0.649 . . . . 1.8799999999999999 111.993 -167.614 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 51.5 t . . . . . 0 N--CA 1.478 0.97 0 CA-C-O 120.0 -0.048 . . . . 3.1499999999999999 110.957 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.502 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.563 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 9.6 t80 -70.51 101.33 1.97 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.742 -0.663 . . . . 1.03 110.521 178.412 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' DBB . . . . . 0.675 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.507 ' H ' ' HD2' ' A' ' 6' ' ' PRO . 6.5 mp -105.94 -39.72 0.17 Allowed Pre-proline 0 CA--C 1.544 0.732 0 N-CA-C 114.936 1.458 . . . . 2.4500000000000002 114.936 -170.608 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.738 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 21.6 Cg_endo -67.59 152.64 77.97 Favored 'Trans proline' 0 C--N 1.356 0.953 0 C-N-CA 121.851 1.701 . . . . 2.0099999999999998 112.823 -173.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.471 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -119.15 87.25 0.41 Allowed Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.804 -0.712 . . . . 4.79 112.851 -177.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -113.97 -43.34 0.8 Allowed Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.943 -0.863 . . . . 4.7800000000000002 110.943 175.619 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -119.35 36.97 3.31 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 109.893 -1.283 . . . . 3.9500000000000002 109.893 172.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.471 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 112.24 -89.09 0.52 Allowed Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 110.507 -1.037 . . . . 1.3400000000000001 110.507 -172.126 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.654 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -151.35 150.4 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.956 0 CA-C-O 121.486 0.66 . . . . 1.1100000000000001 110.088 173.112 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.738 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -59.9 147.12 39.72 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 114.127 -1.397 . . . . 0.54000000000000004 110.399 172.649 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.489 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.439 ' HG ' ' O ' ' A' ' 14' ' ' LEU . 30.4 tp -74.02 84.1 1.77 Allowed 'General case' 0 N--CA 1.444 -0.729 0 CA-C-O 121.449 0.642 . . . . 0.63 111.086 -178.432 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -62.92 -32.69 74.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.836 0.351 . . . . 2.3599999999999999 110.887 179.112 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.563 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 3.7 m -136.55 -87.39 0.32 Allowed 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.681 -0.408 . . . . 0.29999999999999999 111.896 178.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.459 HD11 ' HA ' ' A' ' 2' ' ' DBB . 0.5 OUTLIER -65.24 -28.96 45.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 115.205 -0.907 . . . . 1.8799999999999999 111.105 -169.361 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.546 ' HA ' ' C ' ' A' ' 2' ' ' DBB . 40.1 t . . . . . 0 N--CA 1.481 1.123 0 N-CA-C 111.305 0.113 . . . . 3.1499999999999999 111.305 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.546 ' C ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.416 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 12.0 t80 -76.81 98.91 4.98 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.007 -0.542 . . . . 1.03 109.565 174.33 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' DBB . . . . . 0.644 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.479 ' H ' ' CD ' ' A' ' 6' ' ' PRO . 5.5 mp -113.9 -43.65 0.07 OUTLIER Pre-proline 0 CA--C 1.541 0.632 0 N-CA-C 113.656 0.984 . . . . 2.4500000000000002 113.656 -172.198 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.689 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 51.2 Cg_exo -61.08 146.1 98.09 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.18 1.92 . . . . 2.0099999999999998 113.283 -173.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -76.28 75.11 1.61 Allowed Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.535 -0.757 . . . . 4.79 113.004 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -119.31 75.98 0.3 Allowed Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 110.421 -1.072 . . . . 4.7800000000000002 110.421 174.361 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.51 39.5 5.3 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 110.518 -1.033 . . . . 3.9500000000000002 110.518 -171.519 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.455 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 93.73 -83.28 1.03 Allowed Glycine 0 N--CA 1.444 -0.819 0 N-CA-C 110.455 -1.058 . . . . 1.3400000000000001 110.455 -172.304 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.2 m -132.84 149.33 31.79 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.814 0 CA-C-O 121.822 0.82 . . . . 1.1100000000000001 110.987 173.744 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.689 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -61.04 148.15 41.23 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 113.211 -1.813 . . . . 0.54000000000000004 109.451 168.811 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.458 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 46.0 tp -73.56 86.54 1.59 Allowed 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.318 0.58 . . . . 0.63 110.95 -178.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -59.69 -36.41 76.45 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.451 -0.34 . . . . 2.3599999999999999 110.659 178.667 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.458 ' HB2' ' HA ' ' A' ' 13' ' ' DBB . 3.4 m -134.58 -85.31 0.41 Allowed 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 112.123 0.416 . . . . 0.29999999999999999 112.123 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.45 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER -63.75 -30.51 50.09 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 115.431 -0.804 . . . . 1.8799999999999999 111.582 -168.691 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.459 ' HB3' ' HA ' ' A' ' 2' ' ' DBB . 1.9 t . . . . . 0 N--CA 1.478 0.964 0 N-CA-C 109.397 -0.594 . . . . 3.1499999999999999 109.397 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.459 ' HA ' ' HB3' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.807 ' HD2' ' HB3' ' A' ' 18' ' ' CYS . 22.9 t80 -64.68 111.12 2.61 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.883 -0.598 . . . . 1.03 110.255 176.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' DBB . . . . . 0.584 ' HB2' HD23 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.584 HD23 ' HB2' ' A' ' 4' ' ' DBB . 1.1 pt? -178.3 -36.87 0.0 OUTLIER Pre-proline 0 CA--C 1.546 0.796 0 N-CA-C 112.681 0.623 . . . . 2.4500000000000002 112.681 178.394 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.574 ' CD ' ' HG ' ' A' ' 5' ' ' LEU . 3.3 Cg_endo -91.97 -159.02 0.07 OUTLIER 'Trans proline' 0 C--N 1.366 1.462 0 C-N-CA 122.222 1.948 . . . . 2.0099999999999998 112.405 -175.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.43 38.76 1.42 Allowed Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 121.035 -0.603 . . . . 4.79 112.465 -177.762 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.17 -92.51 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.909 -0.663 . . . . 4.7800000000000002 111.893 179.418 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -81.74 80.98 1.7 Allowed Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 110.738 -0.945 . . . . 3.9500000000000002 110.738 173.6 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.71 -84.49 0.66 Allowed Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.273 -0.731 . . . . 1.3400000000000001 111.273 -171.493 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.608 HG23 ' H ' ' A' ' 12' ' ' CYS . 0.0 OUTLIER -128.84 -88.48 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 120.941 0.401 . . . . 1.1100000000000001 110.535 173.667 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.608 ' H ' HG23 ' A' ' 11' ' ' VAL . 1.5 t -173.84 81.23 0.04 OUTLIER 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 107.74 -1.208 . . . . 0.54000000000000004 107.74 -174.476 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.613 ' O ' ' HB ' ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 52.9 tp -73.96 66.77 1.2 Allowed 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 121.64 0.733 . . . . 0.63 109.654 177.529 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' DBB . . . . . 0.464 ' H ' ' C ' ' A' ' 13' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -59.72 -32.59 70.68 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.382 0.61 . . . . 2.3599999999999999 109.617 174.414 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.807 ' HB3' ' HD2' ' A' ' 3' ' ' PHE . 1.4 m -132.79 -69.32 0.57 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.54 -0.755 . . . . 0.29999999999999999 110.686 179.151 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.613 ' HB ' ' O ' ' A' ' 13' ' ' DBB . 44.2 mm -103.77 -77.33 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 CA-C-N 114.04 -1.436 . . . . 1.8799999999999999 110.996 -169.741 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.544 ' HB3' ' HA ' ' A' ' 2' ' ' DBB . 2.0 t . . . . . 0 N--CA 1.476 0.848 0 N-CA-C 109.223 -0.658 . . . . 3.1499999999999999 109.223 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.544 ' HA ' ' HB3' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -67.28 107.09 2.25 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.066 -0.515 . . . . 1.03 110.616 178.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' DBB . . . . . 0.612 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.673 HD23 ' H ' ' A' ' 5' ' ' LEU . 1.0 OUTLIER -74.11 -35.0 2.18 Favored Pre-proline 0 CA--C 1.55 0.959 0 N-CA-C 114.589 1.329 . . . . 2.4500000000000002 114.589 -174.917 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.986 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 3.6 Cg_exo -78.56 -168.69 0.65 Allowed 'Trans proline' 0 C--N 1.361 1.193 0 C-N-CA 122.154 1.903 . . . . 2.0099999999999998 111.775 -177.395 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.512 ' HA2' ' HA ' ' A' ' 11' ' ' VAL . . . -112.33 -91.2 1.97 Allowed Glycine 0 N--CA 1.442 -0.922 0 C-N-CA 120.465 -0.874 . . . . 4.79 112.586 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.24 38.51 96.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.959 -0.639 . . . . 4.7800000000000002 112.078 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.72 36.72 1.37 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.939 -0.648 . . . . 3.9500000000000002 111.483 -175.443 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.434 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 114.35 -88.96 0.49 Allowed Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 111.319 -0.712 . . . . 1.3400000000000001 111.319 -175.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.582 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 3.1 m -149.72 150.09 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.867 0 CA-C-O 121.745 0.783 . . . . 1.1100000000000001 110.199 175.058 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.986 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -64.95 144.52 57.23 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 113.787 -1.551 . . . . 0.54000000000000004 109.927 171.746 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.595 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.41 ' HB2' ' O ' ' A' ' 11' ' ' VAL . 40.9 tp -71.74 89.42 1.03 Allowed 'General case' 0 N--CA 1.443 -0.789 0 CA-C-O 121.445 0.641 . . . . 0.63 111.797 -174.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 21.1 tp10 -59.78 -40.23 87.55 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 116.285 -0.416 . . . . 2.3599999999999999 110.348 177.149 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.411 ' HB2' ' HA ' ' A' ' 13' ' ' DBB . 7.7 m -131.77 -82.96 0.51 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.126 0.417 . . . . 0.29999999999999999 112.126 176.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.595 HG12 ' O ' ' A' ' 13' ' ' DBB . 28.6 pt -61.21 -27.38 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 112.674 0.62 . . . . 1.8799999999999999 112.674 -167.403 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.56 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 40.5 t . . . . . 0 N--CA 1.479 0.995 0 CA-C-O 119.874 -0.108 . . . . 3.1499999999999999 110.873 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.56 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.564 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 10.8 t80 -72.46 110.29 6.76 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.522 -0.548 . . . . 1.03 109.522 175.123 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' DBB . . . . . 0.704 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.488 ' N ' ' HD3' ' A' ' 6' ' ' PRO . 3.7 pp -69.11 -28.21 1.52 Allowed Pre-proline 0 CA--C 1.552 1.035 0 N-CA-C 115.667 1.728 . . . . 2.4500000000000002 115.667 -172.4 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.981 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 3.9 Cg_exo -83.74 158.18 14.03 Favored 'Trans proline' 0 C--N 1.36 1.167 0 C-N-CA 121.897 1.731 . . . . 2.0099999999999998 112.331 -176.712 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.428 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -109.73 73.53 0.21 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.92 -0.657 . . . . 4.79 112.563 -177.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -112.78 94.9 0.75 Allowed Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 111.301 -0.72 . . . . 4.7800000000000002 111.301 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 80.16 36.68 23.79 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 110.733 -0.947 . . . . 3.9500000000000002 110.733 -171.156 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.428 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 108.16 -93.1 0.78 Allowed Glycine 0 N--CA 1.443 -0.838 0 N-CA-C 111.082 -0.807 . . . . 1.3400000000000001 111.082 -175.106 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 8.5 m -146.94 154.31 12.0 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.925 0 CA-C-O 121.707 0.765 . . . . 1.1100000000000001 110.26 174.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.981 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -71.66 147.49 47.43 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 113.997 -1.456 . . . . 0.54000000000000004 109.358 171.165 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.48 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 55.1 tp -74.44 83.2 1.96 Allowed 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 121.246 0.546 . . . . 0.63 111.01 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -64.21 -34.02 77.13 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.676 0.274 . . . . 2.3599999999999999 111.098 -179.215 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.564 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 3.1 m -133.75 -86.21 0.43 Allowed 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.28 -0.568 . . . . 0.29999999999999999 112.498 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.414 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER -63.46 -30.18 49.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 CA-C-N 115.045 -0.98 . . . . 1.8799999999999999 111.879 -167.194 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.552 ' HB3' HD11 ' A' ' 19' ' ' ILE . 1.8 t . . . . . 0 N--CA 1.476 0.843 0 CA-C-O 118.877 -0.582 . . . . 3.1499999999999999 109.568 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.536 ' HA ' ' HB3' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.561 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 3.4 t80 -68.14 93.77 0.46 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.174 0.512 . . . . 1.03 110.043 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.53 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 9.9 mp -58.86 -53.94 61.39 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 113.163 0.801 . . . . 2.4500000000000002 113.163 -172.538 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.671 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 52.9 Cg_exo -55.87 146.12 69.35 Favored 'Trans proline' 0 C--N 1.358 1.06 0 C-N-CA 122.144 1.896 . . . . 2.0099999999999998 112.872 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -127.39 97.73 0.48 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.086 -0.578 . . . . 4.79 112.749 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -179.81 -152.22 10.61 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.885 -0.674 . . . . 4.7800000000000002 111.591 179.104 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.47 -32.28 68.02 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.079 -0.582 . . . . 3.9500000000000002 111.81 177.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -110.97 99.01 1.09 Allowed Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.499 -0.64 . . . . 1.3400000000000001 111.499 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.9 m -114.8 153.75 16.26 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.75 0 CA-C-O 122.044 0.926 . . . . 1.1100000000000001 112.03 -176.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.671 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -69.4 142.88 53.79 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 113.392 -1.731 . . . . 0.54000000000000004 109.563 170.919 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.45 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.405 ' O ' ' HG ' ' A' ' 14' ' ' LEU . 43.2 tp -73.85 83.84 1.68 Allowed 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.893 -0.594 . . . . 0.63 111.21 -176.855 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -61.57 -27.79 68.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.026 -0.534 . . . . 2.3599999999999999 110.576 177.265 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.561 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 4.6 m -144.52 -85.34 0.13 Allowed 'General case' 0 C--O 1.233 0.212 0 N-CA-C 112.024 0.379 . . . . 0.29999999999999999 112.024 177.754 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.552 HD11 ' HB3' ' A' ' 1' ' ' CYS . 0.5 OUTLIER -66.23 -28.97 45.21 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 CA-C-N 114.638 -1.164 . . . . 1.8799999999999999 112.386 -166.661 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 0.6 OUTLIER . . . . . 0 N--CA 1.48 1.058 0 CA-C-O 119.213 -0.422 . . . . 3.1499999999999999 109.879 . . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.578 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.571 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 4.9 t80 -67.74 111.68 4.4 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.669 -0.696 . . . . 1.03 109.24 173.678 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.984 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 85.2 mt -137.1 -68.18 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.411 0 C-N-CA 121.317 -0.153 . . . . 2.4500000000000002 111.123 175.017 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.984 ' HD3' ' HB2' ' A' ' 5' ' ' LEU . 27.4 Cg_exo -63.46 167.07 13.78 Favored 'Trans proline' 0 C--N 1.356 0.963 0 C-N-CA 122.367 2.045 . . . . 2.0099999999999998 112.381 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -107.53 -25.08 6.15 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.91 -0.662 . . . . 4.79 112.399 -179.404 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -124.19 149.74 16.95 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.55 -0.833 . . . . 4.7800000000000002 112.384 179.389 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 66.88 -128.69 29.25 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 121.078 -0.582 . . . . 3.9500000000000002 112.228 179.503 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.411 ' O ' ' HG2' ' A' ' 6' ' ' PRO . . . -66.96 93.66 0.22 Allowed Glycine 0 N--CA 1.449 -0.452 0 N-CA-C 111.367 -0.693 . . . . 1.3400000000000001 111.367 176.743 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.702 ' O ' ' HB3' ' A' ' 12' ' ' CYS . 2.2 m -88.57 -16.81 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.846 0 N-CA-C 113.186 0.809 . . . . 1.1100000000000001 113.186 -171.513 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.702 ' HB3' ' O ' ' A' ' 11' ' ' VAL . 1.7 t 78.87 120.41 0.05 Allowed 'General case' 0 C--N 1.322 -0.594 0 O-C-N 124.232 0.958 . . . . 0.54000000000000004 108.809 -173.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.411 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 39.4 tp -73.75 93.02 2.06 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-O 121.444 0.64 . . . . 0.63 111.212 -177.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.6 tp10 -59.77 -31.73 69.93 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 115.542 -0.754 . . . . 2.3599999999999999 110.603 176.288 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.571 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 7.8 m -142.91 -82.03 0.19 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.006 0.431 . . . . 0.29999999999999999 111.829 177.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.428 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.2 OUTLIER -66.95 -29.33 45.91 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-N 114.492 -1.231 . . . . 1.8799999999999999 111.678 -167.398 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.518 ' HB3' ' HA ' ' A' ' 2' ' ' DBB . 3.1 t . . . . . 0 N--CA 1.477 0.882 0 N-CA-C 108.747 -0.834 . . . . 3.1499999999999999 108.747 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.518 ' HA ' ' HB3' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.858 ' HD2' ' HB3' ' A' ' 18' ' ' CYS . 18.1 t80 -71.73 120.97 18.08 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.697 -0.853 . . . . 1.03 108.697 170.69 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.411 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 73.7 mt -67.72 -55.97 12.96 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 120.774 -0.37 . . . . 2.4500000000000002 111.541 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.696 ' HG2' ' HA ' ' A' ' 11' ' ' VAL . 36.3 Cg_endo -65.67 154.9 71.8 Favored 'Trans proline' 0 C--N 1.354 0.821 0 C-N-CA 121.806 1.671 . . . . 2.0099999999999998 111.992 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -114.85 -27.46 3.23 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.791 -0.718 . . . . 4.79 112.12 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.17 153.03 17.0 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.811 -0.709 . . . . 4.7800000000000002 112.179 178.603 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 72.98 -141.51 30.43 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.038 -0.601 . . . . 3.9500000000000002 112.561 179.567 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -69.33 90.11 0.28 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 121.407 -0.425 . . . . 1.3400000000000001 112.249 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.696 ' HA ' ' HG2' ' A' ' 6' ' ' PRO . 35.7 m -95.84 160.74 2.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.93 0.872 . . . . 1.1100000000000001 112.178 -175.546 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -70.06 93.12 0.78 Allowed 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 113.247 -1.797 . . . . 0.54000000000000004 110.061 175.315 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.661 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 39.4 tp -73.13 92.18 1.69 Allowed 'General case' 0 N--CA 1.444 -0.765 0 CA-C-O 121.233 0.539 . . . . 0.63 111.649 -177.282 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 73.9 tt0 -59.59 -34.17 72.38 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.972 -0.558 . . . . 2.3599999999999999 110.666 177.074 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.858 ' HB3' ' HD2' ' A' ' 3' ' ' PHE . 10.0 m -136.86 -84.71 0.34 Allowed 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 111.843 0.312 . . . . 0.29999999999999999 111.843 176.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.661 HG12 ' O ' ' A' ' 13' ' ' DBB . 31.4 pt -64.1 -27.62 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 CA-C-N 115.738 -0.665 . . . . 1.8799999999999999 112.072 -168.582 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.721 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 0.7 OUTLIER . . . . . 0 N--CA 1.477 0.907 0 N-CA-C 109.675 -0.491 . . . . 3.1499999999999999 109.675 . . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.721 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -65.78 103.43 0.9 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.994 -0.548 . . . . 1.03 110.959 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' DBB . . . . . 0.416 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.4 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 96.8 mt -59.71 -54.83 51.91 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 112.983 0.734 . . . . 2.4500000000000002 112.983 -173.548 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.478 ' HG2' ' H ' ' A' ' 12' ' ' CYS . 29.1 Cg_endo -63.78 150.88 87.42 Favored 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 121.856 1.704 . . . . 2.0099999999999998 112.333 -178.695 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.577 ' HA2' HG12 ' A' ' 11' ' ' VAL . . . -150.2 50.47 0.54 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.951 -0.642 . . . . 4.79 112.28 -177.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.24 34.82 3.55 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.775 -0.726 . . . . 4.7800000000000002 112.405 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.4 -89.48 0.49 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.681 -0.771 . . . . 3.9500000000000002 111.852 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.45 89.26 0.72 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.788 -0.72 . . . . 1.3400000000000001 111.304 174.115 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.577 HG12 ' HA2' ' A' ' 7' ' ' GLY . 30.5 m -89.41 162.44 2.53 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.797 0 CA-C-O 122.205 1.002 . . . . 1.1100000000000001 111.809 -174.125 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.478 ' H ' ' HG2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -72.86 96.99 2.17 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-N 113.524 -1.671 . . . . 0.54000000000000004 109.235 171.967 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.642 ' O ' ' HB ' ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 48.0 tp -73.79 74.78 1.59 Allowed 'General case' 0 N--CA 1.438 -1.031 0 CA-C-O 121.435 0.636 . . . . 0.63 109.717 178.677 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 -59.4 -37.09 77.11 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.776 -0.647 . . . . 2.3599999999999999 109.678 175.002 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.521 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 1.5 m -129.23 -86.34 0.55 Allowed 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.739 -0.664 . . . . 0.29999999999999999 110.342 175.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.642 ' HB ' ' O ' ' A' ' 13' ' ' DBB . 28.4 mm -68.12 -77.54 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-N 114.702 -1.135 . . . . 1.8799999999999999 111.558 -175.112 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.541 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 40.4 t . . . . . 0 N--CA 1.475 0.806 0 CA-C-O 119.992 -0.052 . . . . 3.1499999999999999 111.066 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.541 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.491 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 13.3 t80 -68.46 108.41 3.27 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.703 -0.681 . . . . 1.03 110.084 177.008 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' DBB . . . . . 0.415 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.59 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 7.9 mp -60.56 -53.28 66.1 Favored Pre-proline 0 N--CA 1.467 0.409 0 N-CA-C 112.53 0.567 . . . . 2.4500000000000002 112.53 -174.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.743 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 14.8 Cg_exo -68.7 92.58 0.43 Allowed 'Trans proline' 0 C--N 1.355 0.921 0 C-N-CA 122.074 1.849 . . . . 2.0099999999999998 111.64 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.571 ' HA2' HG12 ' A' ' 11' ' ' VAL . . . -103.07 83.88 0.45 Allowed Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.81 -0.709 . . . . 4.79 112.119 -177.404 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -170.87 86.07 0.08 OUTLIER Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 111.466 -0.654 . . . . 4.7800000000000002 111.466 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 70.86 -90.6 0.41 Allowed Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 111.456 -0.658 . . . . 3.9500000000000002 111.456 -175.783 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.41 99.96 0.77 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.858 -0.687 . . . . 1.3400000000000001 111.425 173.21 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.571 HG12 ' HA2' ' A' ' 7' ' ' GLY . 33.9 m -113.64 152.66 15.3 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.702 0 CA-C-O 121.995 0.902 . . . . 1.1100000000000001 111.883 -175.797 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.743 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -78.2 136.48 37.81 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 113.294 -1.776 . . . . 0.54000000000000004 108.866 169.791 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.445 ' O ' HG22 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 36.8 tp -72.4 91.17 1.34 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.398 0.618 . . . . 0.63 111.784 -174.037 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -59.32 -35.66 74.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.817 -0.629 . . . . 2.3599999999999999 109.982 176.025 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.491 ' HB3' ' HB3' ' A' ' 3' ' ' PHE . 34.6 m -134.9 -87.82 0.37 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.332 -0.394 . . . . 0.29999999999999999 111.569 175.666 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.445 HG22 ' O ' ' A' ' 13' ' ' DBB . 4.1 tt -55.91 -31.09 29.59 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-N 115.212 -0.904 . . . . 1.8799999999999999 112.989 -170.407 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 42.4 t . . . . . 0 N--CA 1.478 0.952 0 CA-C-O 120.071 -0.014 . . . . 3.1499999999999999 110.972 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.564 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.827 ' HD2' ' HB3' ' A' ' 18' ' ' CYS . 16.3 t80 -67.81 110.86 3.99 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.853 -0.612 . . . . 1.03 109.841 177.291 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.47 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 95.7 mt -71.64 -53.8 7.07 Favored Pre-proline 0 CA--C 1.537 0.474 0 N-CA-C 112.379 0.511 . . . . 2.4500000000000002 112.379 -176.605 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.47 ' HD2' ' N ' ' A' ' 5' ' ' LEU . 20.3 Cg_endo -61.2 144.04 98.75 Favored 'Trans proline' 0 C--N 1.356 0.924 0 C-N-CA 122.067 1.844 . . . . 2.0099999999999998 112.244 -179.258 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -129.18 91.36 0.32 Allowed Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.034 -0.603 . . . . 4.79 112.437 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 175.96 -155.87 20.36 Favored Glycine 0 N--CA 1.449 -0.496 0 N-CA-C 111.276 -0.729 . . . . 4.7800000000000002 111.276 179.509 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.11 93.8 0.78 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.832 -0.699 . . . . 3.9500000000000002 111.75 177.052 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.2 77.96 0.79 Allowed Glycine 0 N--CA 1.444 -0.801 0 N-CA-C 111.011 -0.835 . . . . 1.3400000000000001 111.011 -175.405 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 21.8 m -109.1 167.02 4.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 122.052 0.929 . . . . 1.1100000000000001 112.339 -175.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -67.2 138.88 57.3 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 112.961 -1.927 . . . . 0.54000000000000004 109.346 171.81 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.426 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 32.8 tp -72.68 94.49 1.75 Allowed 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 115.992 -0.549 . . . . 0.63 111.632 -176.423 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -59.86 -32.37 70.64 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.761 -0.654 . . . . 2.3599999999999999 110.462 176.468 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.827 ' HB3' ' HD2' ' A' ' 3' ' ' PHE . 14.4 m -143.4 -85.72 0.14 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.288 -0.414 . . . . 0.29999999999999999 111.814 179.116 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.484 HD13 ' O ' ' A' ' 19' ' ' ILE . 0.2 OUTLIER -64.97 -31.22 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 CA-C-N 114.981 -1.009 . . . . 1.8799999999999999 111.188 -168.307 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.53 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 43.4 t . . . . . 0 N--CA 1.478 0.967 0 CA-C-O 119.825 -0.131 . . . . 3.1499999999999999 110.729 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.53 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.743 ' HD2' ' HB3' ' A' ' 18' ' ' CYS . 48.6 t80 -63.1 106.8 0.91 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.629 -0.714 . . . . 1.03 110.223 175.049 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' DBB . . . . . 0.425 ' HB2' ' H ' ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.454 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 97.8 mt -67.74 -53.6 20.86 Favored Pre-proline 0 CA--C 1.538 0.513 0 N-CA-C 111.866 0.321 . . . . 2.4500000000000002 111.866 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.454 ' HD2' ' N ' ' A' ' 5' ' ' LEU . 34.5 Cg_endo -65.26 151.45 85.31 Favored 'Trans proline' 0 C--N 1.356 0.93 0 C-N-CA 121.978 1.785 . . . . 2.0099999999999998 112.455 -179.696 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -127.41 29.92 4.17 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.046 -0.597 . . . . 4.79 112.287 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -116.27 -136.48 5.85 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.024 -0.608 . . . . 4.7800000000000002 112.345 -179.335 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -71.05 -85.01 0.18 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.149 -0.548 . . . . 3.9500000000000002 112.482 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.64 92.7 0.44 Allowed Glycine 0 N--CA 1.453 -0.225 0 C-N-CA 121.164 -0.541 . . . . 1.3400000000000001 112.005 178.397 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 19.2 m -107.05 -177.19 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.628 0 CA-C-O 122.146 0.974 . . . . 1.1100000000000001 112.242 -175.686 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.89 142.11 29.94 Favored 'General case' 0 N--CA 1.435 -1.211 0 CA-C-N 113.46 -1.7 . . . . 0.54000000000000004 109.344 176.669 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.69 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 29.8 tp -72.64 87.34 1.23 Allowed 'General case' 0 N--CA 1.445 -0.712 0 CA-C-O 121.193 0.521 . . . . 0.63 111.356 -177.058 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -62.77 -30.97 71.85 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.35 -0.386 . . . . 2.3599999999999999 110.792 179.707 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.743 ' HB3' ' HD2' ' A' ' 3' ' ' PHE . 4.8 m -138.67 -83.88 0.28 Allowed 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 112.175 0.435 . . . . 0.29999999999999999 112.175 177.311 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.69 HG12 ' O ' ' A' ' 13' ' ' DBB . 21.5 pt -67.16 -29.42 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 115.606 -0.725 . . . . 1.8799999999999999 111.969 -167.829 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 45.7 t . . . . . 0 N--CA 1.477 0.902 0 CA-C-O 119.943 -0.075 . . . . 3.1499999999999999 110.941 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' DBB . . . . . 0.621 ' HA ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.454 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 31.1 t80 -68.69 102.45 1.51 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.77 -0.65 . . . . 1.03 110.372 178.008 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' DBB . . . . . 0.484 ' HB2' ' H ' ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.484 ' H ' ' HB2' ' A' ' 4' ' ' DBB . 4.3 mm? -61.41 -58.17 20.43 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 118.112 0.415 . . . . 2.4500000000000002 110.855 179.073 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.675 ' HB2' HG12 ' A' ' 11' ' ' VAL . 76.5 Cg_endo -75.11 149.72 36.66 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 121.415 1.41 . . . . 2.0099999999999998 111.133 174.081 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -133.79 28.49 3.22 Favored Glycine 0 CA--C 1.518 0.222 0 C-N-CA 120.64 -0.791 . . . . 4.79 112.928 -177.666 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.87 -90.31 2.16 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.835 -0.698 . . . . 4.7800000000000002 113.021 -178.098 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.8 -94.1 2.24 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.735 -0.745 . . . . 3.9500000000000002 112.534 -177.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.579 ' HA2' HD22 ' A' ' 14' ' ' LEU . . . -70.94 86.31 0.38 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 121.022 -0.609 . . . . 1.3400000000000001 111.597 177.224 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.675 HG12 ' HB2' ' A' ' 6' ' ' PRO . 34.7 m -120.96 176.01 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.706 0 CA-C-O 122.096 0.951 . . . . 1.1100000000000001 112.614 -171.379 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -69.42 132.29 46.11 Favored 'General case' 0 N--CA 1.432 -1.331 0 CA-C-N 112.785 -2.007 . . . . 0.54000000000000004 109.167 170.316 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' DBB . . . . . 0.452 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.579 HD22 ' HA2' ' A' ' 10' ' ' GLY . 36.6 tp -74.1 87.25 1.89 Allowed 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 121.323 0.582 . . . . 0.63 111.144 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -60.45 -29.07 68.79 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.266 -0.424 . . . . 2.3599999999999999 110.33 177.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.454 ' HB3' ' HB3' ' A' ' 3' ' ' PHE . 3.5 m -143.79 -82.18 0.17 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.313 -0.403 . . . . 0.29999999999999999 111.737 177.24 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.621 HG12 ' HA ' ' A' ' 2' ' ' DBB . 0.1 OUTLIER -63.78 -32.2 56.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 CA-C-N 115.324 -0.853 . . . . 1.8799999999999999 111.719 -167.508 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.76 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 4.3 pp . . . . . 0 CA--C 1.548 0.872 0 N-CA-C 114.269 1.211 . . . . 2.45 114.269 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.76 ' HD3' ' HG ' ' A' ' 5' ' ' LEU . 28.4 Cg_exo -63.51 157.03 53.15 Favored 'Trans proline' 0 C--N 1.361 1.233 0 C-N-CA 121.84 1.694 . . . . 2.01 112.806 -178.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -123.13 95.18 0.53 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 121.21 -0.519 . . . . 4.79 112.036 178.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 179.87 -152.86 11.29 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.895 -0.669 . . . . 4.78 112.078 -179.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -90.93 -35.82 7.0 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.782 -0.723 . . . . 3.95 111.678 178.235 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.1 87.67 0.85 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 110.944 -0.862 . . . . 1.34 110.944 175.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.615 HG12 ' HB2' ' A' ' 6' ' ' PRO . 23.8 m -123.99 163.22 23.99 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.638 0 CA-C-O 121.966 0.888 . . . . 1.11 112.24 -173.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.312 -1.054 0 CA-C-N 113.379 -1.737 . . . . 0.54 109.957 173.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.401 ' OE1' ' HA ' ' A' ' 17' ' ' GLU . 4.3 tp10 . . . . . 0 N--CA 1.452 -0.342 0 CA-C-O 120.698 0.285 . . . . 2.36 110.86 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 8.1 m -138.37 -83.89 0.29 Allowed 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.103 0.408 . . . . 0.3 112.103 178.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 29.9 pt . . . . . 0 C--N 1.341 0.234 0 CA-C-N 115.819 -0.628 . . . . 1.88 112.076 -167.655 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.794 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 3.4 pp . . . . . 0 CA--C 1.547 0.837 0 N-CA-C 113.175 0.805 . . . . 2.45 113.175 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.794 ' HD3' ' HG ' ' A' ' 5' ' ' LEU . 68.6 Cg_endo -96.27 -159.97 0.06 OUTLIER 'Trans proline' 0 C--N 1.361 1.225 0 C-N-CA 121.867 1.711 . . . . 2.01 112.441 -178.163 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -112.49 -86.96 1.62 Allowed Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.637 -0.792 . . . . 4.79 111.991 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 63.69 37.32 94.55 Favored Glycine 0 N--CA 1.452 -0.269 0 N-CA-C 111.394 -0.682 . . . . 4.78 111.394 -177.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.05 -79.55 0.36 Allowed Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 110.899 -0.88 . . . . 3.95 110.899 -172.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.79 -77.01 0.46 Allowed Glycine 0 N--CA 1.442 -0.916 0 N-CA-C 110.801 -0.92 . . . . 1.34 110.801 172.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 10.2 m -149.49 173.55 1.35 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.747 0 CA-C-O 121.561 0.696 . . . . 1.11 110.504 175.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.435 ' CB ' ' HD2' ' A' ' 6' ' ' PRO . 1.0 OUTLIER . . . . . 0 C--N 1.303 -1.434 0 CA-C-N 113.571 -1.649 . . . . 0.54 108.65 168.273 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 43.9 tp10 . . . . . 0 N--CA 1.454 -0.243 0 CA-C-O 120.791 0.329 . . . . 2.36 110.836 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.445 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 7.6 m -141.74 -82.85 0.21 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.101 0.477 . . . . 0.3 111.693 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.445 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER . . . . . 0 N--CA 1.452 -0.355 0 CA-C-N 114.771 -1.104 . . . . 1.88 111.179 -168.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.674 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 4.9 mp . . . . . 0 CA--C 1.54 0.579 0 N-CA-C 112.808 0.67 . . . . 2.45 112.808 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.674 ' HD3' ' HB2' ' A' ' 5' ' ' LEU . 5.0 Cg_exo -79.76 164.25 23.18 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 122.64 2.227 . . . . 2.01 112.496 -174.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.591 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -70.98 -93.73 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.854 -0.612 . . . . 4.79 112.238 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.8 35.79 90.69 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 121.158 -0.544 . . . . 4.78 112.578 178.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 108.43 34.29 2.72 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.742 -0.742 . . . . 3.95 111.467 -176.282 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.591 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 116.72 -92.4 0.56 Allowed Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 111.446 -0.661 . . . . 1.34 111.446 -176.441 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 6.5 m -150.55 154.11 9.26 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.723 0 CA-C-O 121.615 0.722 . . . . 1.11 110.188 176.387 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.575 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.305 -1.365 0 CA-C-N 114.115 -1.402 . . . . 0.54 109.342 172.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 13.8 tp10 . . . . . 0 N--CA 1.453 -0.285 0 CA-C-O 120.918 0.389 . . . . 2.36 110.616 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.473 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 6.0 m -131.75 -86.56 0.48 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.336 -0.393 . . . . 0.3 111.873 -177.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.473 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.3 OUTLIER . . . . . 0 CA--C 1.533 0.316 0 CA-C-N 115.036 -0.984 . . . . 1.88 111.348 -168.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.634 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 1.5 pt? . . . . . 0 CA--C 1.542 0.661 0 N-CA-C 114.134 1.161 . . . . 2.45 114.134 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.663 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 20.8 Cg_exo -68.72 151.51 74.59 Favored 'Trans proline' 0 C--N 1.358 1.066 0 C-N-CA 121.647 1.564 . . . . 2.01 112.23 -177.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.43 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -110.96 54.1 0.55 Allowed Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.761 -0.654 . . . . 4.79 112.312 -178.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -112.34 80.81 0.28 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.746 -0.74 . . . . 4.78 111.278 177.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.1 28.51 5.82 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.159 -0.776 . . . . 3.95 111.159 -175.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.43 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 108.24 -113.57 3.89 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.181 -0.768 . . . . 1.34 111.181 -176.046 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.8 m -132.26 156.14 42.15 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.77 0 CA-C-O 121.745 0.783 . . . . 1.11 110.458 173.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.663 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.304 -1.381 0 CA-C-N 113.812 -1.54 . . . . 0.54 110.323 174.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 . . . . . 0 N--CA 1.452 -0.356 0 CA-C-O 120.485 0.183 . . . . 2.36 110.523 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.413 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 4.9 m -136.67 -84.93 0.34 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.94 -0.304 . . . . 0.3 111.769 176.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.413 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 24.5 pt . . . . . 0 N--CA 1.451 -0.375 0 CA-C-N 115.773 -0.649 . . . . 1.88 111.993 -167.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.486 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 6.5 mp . . . . . 0 CA--C 1.544 0.732 0 N-CA-C 114.936 1.458 . . . . 2.45 114.936 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.738 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 21.6 Cg_endo -67.59 152.64 77.97 Favored 'Trans proline' 0 C--N 1.356 0.953 0 C-N-CA 121.851 1.701 . . . . 2.01 112.823 -173.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.471 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -119.15 87.25 0.41 Allowed Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.804 -0.712 . . . . 4.79 112.851 -177.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -113.97 -43.34 0.8 Allowed Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.943 -0.863 . . . . 4.78 110.943 175.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -119.35 36.97 3.31 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 109.893 -1.283 . . . . 3.95 109.893 172.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.471 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 112.24 -89.09 0.52 Allowed Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 110.507 -1.037 . . . . 1.34 110.507 -172.126 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.654 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -151.35 150.4 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.956 0 CA-C-O 121.486 0.66 . . . . 1.11 110.088 173.112 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.738 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.303 -1.431 0 CA-C-N 114.127 -1.397 . . . . 0.54 110.399 172.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 . . . . . 0 N--CA 1.454 -0.254 0 CA-C-O 120.836 0.351 . . . . 2.36 110.887 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.422 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.7 m -136.55 -87.39 0.32 Allowed 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.681 -0.408 . . . . 0.3 111.896 178.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.422 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.5 OUTLIER . . . . . 0 CA--C 1.535 0.376 0 CA-C-N 115.205 -0.907 . . . . 1.88 111.105 -169.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.437 ' N ' HD12 ' A' ' 5' ' ' LEU . 5.5 mp . . . . . 0 CA--C 1.541 0.632 0 N-CA-C 113.656 0.984 . . . . 2.45 113.656 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.689 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 51.2 Cg_exo -61.08 146.1 98.09 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.18 1.92 . . . . 2.01 113.283 -173.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -76.28 75.11 1.61 Allowed Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.535 -0.757 . . . . 4.79 113.004 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -119.31 75.98 0.3 Allowed Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 110.421 -1.072 . . . . 4.78 110.421 174.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.51 39.5 5.3 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 110.518 -1.033 . . . . 3.95 110.518 -171.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.455 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 93.73 -83.28 1.03 Allowed Glycine 0 N--CA 1.444 -0.819 0 N-CA-C 110.455 -1.058 . . . . 1.34 110.455 -172.304 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.2 m -132.84 149.33 31.79 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.814 0 CA-C-O 121.822 0.82 . . . . 1.11 110.987 173.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.689 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.303 -1.44 0 CA-C-N 113.211 -1.813 . . . . 0.54 109.451 168.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 . . . . . 0 N--CA 1.454 -0.231 0 CA-C-O 120.776 0.322 . . . . 2.36 110.659 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.45 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.4 m -134.58 -85.31 0.41 Allowed 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 112.123 0.416 . . . . 0.3 112.123 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.45 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER . . . . . 0 CA--C 1.535 0.377 0 CA-C-N 115.431 -0.804 . . . . 1.88 111.582 -168.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.574 ' HG ' ' CD ' ' A' ' 6' ' ' PRO . 1.1 pt? . . . . . 0 CA--C 1.546 0.796 0 N-CA-C 112.681 0.623 . . . . 2.45 112.681 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.574 ' CD ' ' HG ' ' A' ' 5' ' ' LEU . 3.3 Cg_endo -91.97 -159.02 0.07 OUTLIER 'Trans proline' 0 C--N 1.366 1.462 0 C-N-CA 122.222 1.948 . . . . 2.01 112.405 -175.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.43 38.76 1.42 Allowed Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 121.035 -0.603 . . . . 4.79 112.465 -177.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.17 -92.51 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.909 -0.663 . . . . 4.78 111.893 179.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -81.74 80.98 1.7 Allowed Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 110.738 -0.945 . . . . 3.95 110.738 173.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.71 -84.49 0.66 Allowed Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.273 -0.731 . . . . 1.34 111.273 -171.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.608 HG23 ' H ' ' A' ' 12' ' ' CYS . 0.0 OUTLIER -128.84 -88.48 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 120.941 0.401 . . . . 1.11 110.535 173.667 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.608 ' H ' HG23 ' A' ' 11' ' ' VAL . 1.5 t . . . . . 0 N--CA 1.441 -0.891 0 N-CA-C 107.74 -1.208 . . . . 0.54 107.74 -174.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 . . . . . 0 N--CA 1.455 -0.212 0 CA-C-O 121.382 0.61 . . . . 2.36 109.617 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 1.4 m -132.79 -69.32 0.57 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.54 -0.755 . . . . 0.3 110.686 179.151 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 44.2 mm . . . . . 0 N--CA 1.447 -0.587 0 CA-C-N 114.04 -1.436 . . . . 1.88 110.996 -169.741 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.562 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 1.0 OUTLIER . . . . . 0 CA--C 1.55 0.959 0 N-CA-C 114.589 1.329 . . . . 2.45 114.589 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.986 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 3.6 Cg_exo -78.56 -168.69 0.65 Allowed 'Trans proline' 0 C--N 1.361 1.193 0 C-N-CA 122.154 1.903 . . . . 2.01 111.775 -177.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.512 ' HA2' ' HA ' ' A' ' 11' ' ' VAL . . . -112.33 -91.2 1.97 Allowed Glycine 0 N--CA 1.442 -0.922 0 C-N-CA 120.465 -0.874 . . . . 4.79 112.586 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.24 38.51 96.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.959 -0.639 . . . . 4.78 112.078 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.72 36.72 1.37 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.939 -0.648 . . . . 3.95 111.483 -175.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.434 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 114.35 -88.96 0.49 Allowed Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 111.319 -0.712 . . . . 1.34 111.319 -175.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.582 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 3.1 m -149.72 150.09 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.867 0 CA-C-O 121.745 0.783 . . . . 1.11 110.199 175.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.986 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.304 -1.371 0 CA-C-N 113.787 -1.551 . . . . 0.54 109.927 171.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 21.1 tp10 . . . . . 0 N--CA 1.45 -0.437 0 CA-C-O 120.691 0.281 . . . . 2.36 110.348 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 7.7 m -131.77 -82.96 0.51 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.126 0.417 . . . . 0.3 112.126 176.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 28.6 pt . . . . . 0 N--CA 1.455 -0.176 0 N-CA-C 112.674 0.62 . . . . 1.88 112.674 -167.403 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.488 ' N ' ' HD3' ' A' ' 6' ' ' PRO . 3.7 pp . . . . . 0 CA--C 1.552 1.035 0 N-CA-C 115.667 1.728 . . . . 2.45 115.667 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.981 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 3.9 Cg_exo -83.74 158.18 14.03 Favored 'Trans proline' 0 C--N 1.36 1.167 0 C-N-CA 121.897 1.731 . . . . 2.01 112.331 -176.712 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.428 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -109.73 73.53 0.21 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.92 -0.657 . . . . 4.79 112.563 -177.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -112.78 94.9 0.75 Allowed Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 111.301 -0.72 . . . . 4.78 111.301 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 80.16 36.68 23.79 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 110.733 -0.947 . . . . 3.95 110.733 -171.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.428 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 108.16 -93.1 0.78 Allowed Glycine 0 N--CA 1.443 -0.838 0 N-CA-C 111.082 -0.807 . . . . 1.34 111.082 -175.106 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 8.5 m -146.94 154.31 12.0 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.925 0 CA-C-O 121.707 0.765 . . . . 1.11 110.26 174.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.981 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.302 -1.498 0 CA-C-N 113.997 -1.456 . . . . 0.54 109.358 171.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 . . . . . 0 N--CA 1.453 -0.292 0 CA-C-O 120.676 0.274 . . . . 2.36 111.098 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.414 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.1 m -133.75 -86.21 0.43 Allowed 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.28 -0.568 . . . . 0.3 112.498 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.414 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER . . . . . 0 CA--C 1.538 0.497 0 CA-C-N 115.045 -0.98 . . . . 1.88 111.879 -167.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.53 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 9.9 mp . . . . . 0 CA--C 1.538 0.489 0 N-CA-C 113.163 0.801 . . . . 2.45 113.163 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.671 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 52.9 Cg_exo -55.87 146.12 69.35 Favored 'Trans proline' 0 C--N 1.358 1.06 0 C-N-CA 122.144 1.896 . . . . 2.01 112.872 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -127.39 97.73 0.48 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.086 -0.578 . . . . 4.79 112.749 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -179.81 -152.22 10.61 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.885 -0.674 . . . . 4.78 111.591 179.104 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.47 -32.28 68.02 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.079 -0.582 . . . . 3.95 111.81 177.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -110.97 99.01 1.09 Allowed Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.499 -0.64 . . . . 1.34 111.499 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.9 m -114.8 153.75 16.26 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.75 0 CA-C-O 122.044 0.926 . . . . 1.11 112.03 -176.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.671 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.308 -1.213 0 CA-C-N 113.392 -1.731 . . . . 0.54 109.563 170.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 . . . . . 0 N--CA 1.454 -0.255 0 CA-C-O 120.634 0.255 . . . . 2.36 110.576 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.429 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 4.6 m -144.52 -85.34 0.13 Allowed 'General case' 0 C--O 1.233 0.212 0 N-CA-C 112.024 0.379 . . . . 0.3 112.024 177.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.429 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.5 OUTLIER . . . . . 0 CA--C 1.537 0.469 0 CA-C-N 114.638 -1.164 . . . . 1.88 112.386 -166.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.984 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 85.2 mt . . . . . 0 CA--C 1.536 0.411 0 CA-C-O 119.824 -0.131 . . . . 2.45 111.123 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.984 ' HD3' ' HB2' ' A' ' 5' ' ' LEU . 27.4 Cg_exo -63.46 167.07 13.78 Favored 'Trans proline' 0 C--N 1.356 0.963 0 C-N-CA 122.367 2.045 . . . . 2.01 112.381 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -107.53 -25.08 6.15 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.91 -0.662 . . . . 4.79 112.399 -179.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -124.19 149.74 16.95 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.55 -0.833 . . . . 4.78 112.384 179.389 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 66.88 -128.69 29.25 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 121.078 -0.582 . . . . 3.95 112.228 179.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.411 ' O ' ' HG2' ' A' ' 6' ' ' PRO . . . -66.96 93.66 0.22 Allowed Glycine 0 N--CA 1.449 -0.452 0 N-CA-C 111.367 -0.693 . . . . 1.34 111.367 176.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.702 ' O ' ' HB3' ' A' ' 12' ' ' CYS . 2.2 m -88.57 -16.81 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.846 0 N-CA-C 113.186 0.809 . . . . 1.11 113.186 -171.513 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.702 ' HB3' ' O ' ' A' ' 11' ' ' VAL . 1.7 t . . . . . 0 C--N 1.322 -0.594 0 O-C-N 124.232 0.958 . . . . 0.54 108.809 -173.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.6 tp10 . . . . . 0 N--CA 1.451 -0.378 0 CA-C-O 120.791 0.329 . . . . 2.36 110.603 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.428 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 7.8 m -142.91 -82.03 0.19 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.006 0.431 . . . . 0.3 111.829 177.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.428 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.2 OUTLIER . . . . . 0 CA--C 1.534 0.348 0 CA-C-N 114.492 -1.231 . . . . 1.88 111.678 -167.398 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.411 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 73.7 mt . . . . . 0 CA--C 1.536 0.435 0 N-CA-C 111.541 0.2 . . . . 2.45 111.541 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.696 ' HG2' ' HA ' ' A' ' 11' ' ' VAL . 36.3 Cg_endo -65.67 154.9 71.8 Favored 'Trans proline' 0 C--N 1.354 0.821 0 C-N-CA 121.806 1.671 . . . . 2.01 111.992 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -114.85 -27.46 3.23 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.791 -0.718 . . . . 4.79 112.12 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.17 153.03 17.0 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.811 -0.709 . . . . 4.78 112.179 178.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 72.98 -141.51 30.43 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.038 -0.601 . . . . 3.95 112.561 179.567 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -69.33 90.11 0.28 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 121.407 -0.425 . . . . 1.34 112.249 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.696 ' HA ' ' HG2' ' A' ' 6' ' ' PRO . 35.7 m -95.84 160.74 2.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.93 0.872 . . . . 1.11 112.178 -175.546 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.311 -1.066 0 CA-C-N 113.247 -1.797 . . . . 0.54 110.061 175.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 73.9 tt0 . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 120.705 0.288 . . . . 2.36 110.666 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 10.0 m -136.86 -84.71 0.34 Allowed 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 111.843 0.312 . . . . 0.3 111.843 176.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 31.4 pt . . . . . 0 N--CA 1.45 -0.44 0 CA-C-N 115.738 -0.665 . . . . 1.88 112.072 -168.582 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.4 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 96.8 mt . . . . . 0 CA--C 1.539 0.542 0 N-CA-C 112.983 0.734 . . . . 2.45 112.983 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.478 ' HG2' ' H ' ' A' ' 12' ' ' CYS . 29.1 Cg_endo -63.78 150.88 87.42 Favored 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 121.856 1.704 . . . . 2.01 112.333 -178.695 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.577 ' HA2' HG12 ' A' ' 11' ' ' VAL . . . -150.2 50.47 0.54 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.951 -0.642 . . . . 4.79 112.28 -177.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.24 34.82 3.55 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.775 -0.726 . . . . 4.78 112.405 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.4 -89.48 0.49 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.681 -0.771 . . . . 3.95 111.852 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.45 89.26 0.72 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.788 -0.72 . . . . 1.34 111.304 174.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.577 HG12 ' HA2' ' A' ' 7' ' ' GLY . 30.5 m -89.41 162.44 2.53 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.797 0 CA-C-O 122.205 1.002 . . . . 1.11 111.809 -174.125 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.478 ' H ' ' HG2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.432 -1.37 0 CA-C-N 113.524 -1.671 . . . . 0.54 109.235 171.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 . . . . . 0 N--CA 1.454 -0.256 0 N-CA-C 109.678 -0.49 . . . . 2.36 109.678 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.521 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 1.5 m -129.23 -86.34 0.55 Allowed 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.739 -0.664 . . . . 0.3 110.342 175.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.521 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 28.4 mm . . . . . 0 N--CA 1.448 -0.566 0 CA-C-N 114.702 -1.135 . . . . 1.88 111.558 -175.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.59 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 7.9 mp . . . . . 0 N--CA 1.467 0.409 0 N-CA-C 112.53 0.567 . . . . 2.45 112.53 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.743 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 14.8 Cg_exo -68.7 92.58 0.43 Allowed 'Trans proline' 0 C--N 1.355 0.921 0 C-N-CA 122.074 1.849 . . . . 2.01 111.64 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.571 ' HA2' HG12 ' A' ' 11' ' ' VAL . . . -103.07 83.88 0.45 Allowed Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.81 -0.709 . . . . 4.79 112.119 -177.404 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -170.87 86.07 0.08 OUTLIER Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 111.466 -0.654 . . . . 4.78 111.466 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 70.86 -90.6 0.41 Allowed Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 111.456 -0.658 . . . . 3.95 111.456 -175.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.41 99.96 0.77 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.858 -0.687 . . . . 1.34 111.425 173.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.571 HG12 ' HA2' ' A' ' 7' ' ' GLY . 33.9 m -113.64 152.66 15.3 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.702 0 CA-C-O 121.995 0.902 . . . . 1.11 111.883 -175.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.743 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--N 1.306 -1.29 0 CA-C-N 113.294 -1.776 . . . . 0.54 108.866 169.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 . . . . . 0 N--CA 1.452 -0.372 0 N-CA-C 109.982 -0.377 . . . . 2.36 109.982 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 34.6 m -134.9 -87.82 0.37 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.332 -0.394 . . . . 0.3 111.569 175.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 4.1 tt . . . . . 0 CA--C 1.535 0.388 0 CA-C-N 115.212 -0.904 . . . . 1.88 112.989 -170.407 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.47 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 95.7 mt . . . . . 0 CA--C 1.537 0.474 0 N-CA-C 112.379 0.511 . . . . 2.45 112.379 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.47 ' HD2' ' N ' ' A' ' 5' ' ' LEU . 20.3 Cg_endo -61.2 144.04 98.75 Favored 'Trans proline' 0 C--N 1.356 0.924 0 C-N-CA 122.067 1.844 . . . . 2.01 112.244 -179.258 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -129.18 91.36 0.32 Allowed Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.034 -0.603 . . . . 4.79 112.437 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 175.96 -155.87 20.36 Favored Glycine 0 N--CA 1.449 -0.496 0 N-CA-C 111.276 -0.729 . . . . 4.78 111.276 179.509 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.11 93.8 0.78 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.832 -0.699 . . . . 3.95 111.75 177.052 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.2 77.96 0.79 Allowed Glycine 0 N--CA 1.444 -0.801 0 N-CA-C 111.011 -0.835 . . . . 1.34 111.011 -175.405 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 21.8 m -109.1 167.02 4.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 122.052 0.929 . . . . 1.11 112.339 -175.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.309 -1.153 0 CA-C-N 112.961 -1.927 . . . . 0.54 109.346 171.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 . . . . . 0 N--CA 1.455 -0.214 0 CA-C-O 120.872 0.368 . . . . 2.36 110.462 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.468 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 14.4 m -143.4 -85.72 0.14 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.288 -0.414 . . . . 0.3 111.814 179.116 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.484 HD13 ' O ' ' A' ' 19' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.452 -0.368 0 CA-C-N 114.981 -1.009 . . . . 1.88 111.188 -168.307 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.454 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 97.8 mt . . . . . 0 CA--C 1.538 0.513 0 N-CA-C 111.866 0.321 . . . . 2.45 111.866 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.454 ' HD2' ' N ' ' A' ' 5' ' ' LEU . 34.5 Cg_endo -65.26 151.45 85.31 Favored 'Trans proline' 0 C--N 1.356 0.93 0 C-N-CA 121.978 1.785 . . . . 2.01 112.455 -179.696 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -127.41 29.92 4.17 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.046 -0.597 . . . . 4.79 112.287 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -116.27 -136.48 5.85 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.024 -0.608 . . . . 4.78 112.345 -179.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -71.05 -85.01 0.18 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.149 -0.548 . . . . 3.95 112.482 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.64 92.7 0.44 Allowed Glycine 0 N--CA 1.453 -0.225 0 C-N-CA 121.164 -0.541 . . . . 1.34 112.005 178.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 19.2 m -107.05 -177.19 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.628 0 CA-C-O 122.146 0.974 . . . . 1.11 112.242 -175.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.435 -1.211 0 CA-C-N 113.46 -1.7 . . . . 0.54 109.344 176.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 . . . . . 0 CA--C 1.53 0.185 0 CA-C-O 120.815 0.34 . . . . 2.36 110.792 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.4 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 4.8 m -138.67 -83.88 0.28 Allowed 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 112.175 0.435 . . . . 0.3 112.175 177.311 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.4 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 21.5 pt . . . . . 0 N--CA 1.45 -0.457 0 CA-C-N 115.606 -0.725 . . . . 1.88 111.969 -167.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.456 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 4.3 mm? . . . . . 0 CA--C 1.533 0.315 0 CA-C-O 119.816 -0.135 . . . . 2.45 110.855 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.675 ' HB2' HG12 ' A' ' 11' ' ' VAL . 76.5 Cg_endo -75.11 149.72 36.66 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 121.415 1.41 . . . . 2.01 111.133 174.081 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -133.79 28.49 3.22 Favored Glycine 0 CA--C 1.518 0.222 0 C-N-CA 120.64 -0.791 . . . . 4.79 112.928 -177.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.87 -90.31 2.16 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.835 -0.698 . . . . 4.78 113.021 -178.098 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.8 -94.1 2.24 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.735 -0.745 . . . . 3.95 112.534 -177.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.94 86.31 0.38 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 121.022 -0.609 . . . . 1.34 111.597 177.224 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.675 HG12 ' HB2' ' A' ' 6' ' ' PRO . 34.7 m -120.96 176.01 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.706 0 CA-C-O 122.096 0.951 . . . . 1.11 112.614 -171.379 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.432 -1.331 0 CA-C-N 112.785 -2.007 . . . . 0.54 109.167 170.316 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 . . . . . 0 N--CA 1.453 -0.28 0 CA-C-O 120.776 0.322 . . . . 2.36 110.33 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.414 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 3.5 m -143.79 -82.18 0.17 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.313 -0.403 . . . . 0.3 111.737 177.24 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.488 HD13 ' O ' ' A' ' 19' ' ' ILE . 0.1 OUTLIER . . . . . 0 CA--C 1.537 0.471 0 CA-C-N 115.324 -0.853 . . . . 1.88 111.719 -167.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.672 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 40.6 t . . . . . 0 N--CA 1.477 0.883 0 CA-C-O 119.928 -0.082 . . . . 3.15 110.963 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.672 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.812 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 28.6 t80 -58.25 106.61 0.39 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.686 -0.688 . . . . 1.03 110.951 -179.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . 0.433 ' HB2' ' H ' ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.76 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 4.3 pp -70.48 -35.49 4.77 Favored Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 114.269 1.211 . . . . 2.45 114.269 -173.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.76 ' HD3' ' HG ' ' A' ' 5' ' ' LEU . 28.4 Cg_exo -63.51 157.03 53.15 Favored 'Trans proline' 0 C--N 1.361 1.233 0 C-N-CA 121.84 1.694 . . . . 2.01 112.806 -178.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -123.13 95.18 0.53 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 121.21 -0.519 . . . . 4.79 112.036 178.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 179.87 -152.86 11.29 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.895 -0.669 . . . . 4.78 112.078 -179.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -90.93 -35.82 7.0 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.782 -0.723 . . . . 3.95 111.678 178.235 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.1 87.67 0.85 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 110.944 -0.862 . . . . 1.34 110.944 175.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.615 HG12 ' HB2' ' A' ' 6' ' ' PRO . 23.8 m -123.99 163.22 23.99 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.638 0 CA-C-O 121.966 0.888 . . . . 1.11 112.24 -173.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -61.43 137.08 58.23 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 113.379 -1.737 . . . . 0.54 109.957 173.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.621 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 51.9 tp -72.3 92.32 1.39 Allowed 'General case' 0 N--CA 1.444 -0.729 0 CA-C-O 121.364 0.602 . . . . 0.63 111.681 -176.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.401 ' OE1' ' HA ' ' A' ' 17' ' ' GLU . 4.3 tp10 -61.9 -32.69 73.09 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.286 -0.415 . . . . 2.36 110.86 179.29 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.812 ' HB3' ' HB3' ' A' ' 3' ' ' PHE . 8.1 m -138.37 -83.89 0.29 Allowed 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.103 0.408 . . . . 0.3 112.103 178.355 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.621 HG12 ' O ' ' A' ' 13' ' ' DBB . 29.9 pt -61.97 -31.68 51.95 Favored 'Isoleucine or valine' 0 C--N 1.341 0.234 0 CA-C-N 115.819 -0.628 . . . . 1.88 112.076 -167.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.551 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 41.9 t . . . . . 0 N--CA 1.479 0.991 0 CA-C-O 120.305 0.098 . . . . 3.15 111.188 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.746 ' HA ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -67.03 106.37 1.93 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.269 -0.423 . . . . 1.03 110.662 176.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.794 ' HG ' ' HD3' ' A' ' 6' ' ' PRO . 3.4 pp -175.62 -35.12 0.0 OUTLIER Pre-proline 0 CA--C 1.547 0.837 0 N-CA-C 113.175 0.805 . . . . 2.45 113.175 175.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.794 ' HD3' ' HG ' ' A' ' 5' ' ' LEU . 68.6 Cg_endo -96.27 -159.97 0.06 OUTLIER 'Trans proline' 0 C--N 1.361 1.225 0 C-N-CA 121.867 1.711 . . . . 2.01 112.441 -178.163 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -112.49 -86.96 1.62 Allowed Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.637 -0.792 . . . . 4.79 111.991 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 63.69 37.32 94.55 Favored Glycine 0 N--CA 1.452 -0.269 0 N-CA-C 111.394 -0.682 . . . . 4.78 111.394 -177.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.05 -79.55 0.36 Allowed Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 110.899 -0.88 . . . . 3.95 110.899 -172.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.79 -77.01 0.46 Allowed Glycine 0 N--CA 1.442 -0.916 0 N-CA-C 110.801 -0.92 . . . . 1.34 110.801 172.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 10.2 m -149.49 173.55 1.35 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.747 0 CA-C-O 121.561 0.696 . . . . 1.11 110.504 175.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.435 ' CB ' ' HD2' ' A' ' 6' ' ' PRO . 1.0 OUTLIER -72.84 132.77 43.97 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 113.571 -1.649 . . . . 0.54 108.65 168.273 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.431 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 36.0 tp -73.28 92.35 1.78 Allowed 'General case' 0 N--CA 1.444 -0.753 0 CA-C-O 121.003 0.43 . . . . 0.63 111.372 -178.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 43.9 tp10 -59.54 -31.28 69.26 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.034 -0.53 . . . . 2.36 110.836 177.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.445 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 7.6 m -141.74 -82.85 0.21 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.101 0.477 . . . . 0.3 111.693 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.746 HG12 ' HA ' ' A' ' 2' ' ' DBB . 0.4 OUTLIER -69.85 -31.72 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.355 0 CA-C-N 114.771 -1.104 . . . . 1.88 111.179 -168.787 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 41.6 t . . . . . 0 N--CA 1.476 0.846 0 CA-C-O 119.959 -0.067 . . . . 3.15 110.869 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.573 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.445 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 14.5 t80 -70.29 111.22 5.73 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.794 -0.639 . . . . 1.03 110.604 178.281 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . 0.625 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.674 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 4.9 mp -130.79 -54.71 0.03 OUTLIER Pre-proline 0 CA--C 1.54 0.579 0 N-CA-C 112.808 0.67 . . . . 2.45 112.808 -175.124 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.674 ' HD3' ' HB2' ' A' ' 5' ' ' LEU . 5.0 Cg_exo -79.76 164.25 23.18 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 122.64 2.227 . . . . 2.01 112.496 -174.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.591 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -70.98 -93.73 0.07 OUTLIER Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.854 -0.612 . . . . 4.79 112.238 179.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.8 35.79 90.69 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 121.158 -0.544 . . . . 4.78 112.578 178.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 108.43 34.29 2.72 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.742 -0.742 . . . . 3.95 111.467 -176.282 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.591 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 116.72 -92.4 0.56 Allowed Glycine 0 N--CA 1.445 -0.735 0 N-CA-C 111.446 -0.661 . . . . 1.34 111.446 -176.441 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 6.5 m -150.55 154.11 9.26 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.723 0 CA-C-O 121.615 0.722 . . . . 1.11 110.188 176.387 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.625 ' O ' ' HA ' ' A' ' 4' ' ' DBB . 0.0 OUTLIER -65.85 136.29 55.97 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 114.115 -1.402 . . . . 0.54 109.342 172.104 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.462 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 39.5 tp -73.0 91.47 1.57 Allowed 'General case' 0 N--CA 1.443 -0.776 0 CA-C-O 121.205 0.526 . . . . 0.63 111.265 -177.258 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 13.8 tp10 -63.24 -35.25 79.7 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.918 0.389 . . . . 2.36 110.616 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.473 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 6.0 m -131.75 -86.56 0.48 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.336 -0.393 . . . . 0.3 111.873 -177.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.473 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.3 OUTLIER -67.8 -31.15 51.0 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 CA-C-N 115.036 -0.984 . . . . 1.88 111.348 -168.596 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.625 ' HA ' ' C ' ' A' ' 2' ' ' DBB . 44.4 t . . . . . 0 N--CA 1.48 1.064 0 N-CA-C 111.513 0.19 . . . . 3.15 111.513 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.625 ' C ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.502 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 4.1 t80 -79.68 94.06 5.64 Favored 'General case' 0 N--CA 1.45 -0.446 0 N-CA-C 109.585 -0.524 . . . . 1.03 109.585 177.507 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . 0.681 ' HB2' HD23 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.681 HD23 ' HB2' ' A' ' 4' ' ' DBB . 1.5 pt? -165.68 -38.44 0.0 OUTLIER Pre-proline 0 CA--C 1.542 0.661 0 N-CA-C 114.134 1.161 . . . . 2.45 114.134 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.663 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 20.8 Cg_exo -68.72 151.51 74.59 Favored 'Trans proline' 0 C--N 1.358 1.066 0 C-N-CA 121.647 1.564 . . . . 2.01 112.23 -177.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.43 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -110.96 54.1 0.55 Allowed Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.761 -0.654 . . . . 4.79 112.312 -178.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -112.34 80.81 0.28 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.746 -0.74 . . . . 4.78 111.278 177.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.1 28.51 5.82 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.159 -0.776 . . . . 3.95 111.159 -175.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.43 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 108.24 -113.57 3.89 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.181 -0.768 . . . . 1.34 111.181 -176.046 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.8 m -132.26 156.14 42.15 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.77 0 CA-C-O 121.745 0.783 . . . . 1.11 110.458 173.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.663 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -67.11 99.37 0.66 Allowed 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 113.812 -1.54 . . . . 0.54 110.323 174.969 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.648 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 42.1 tp -73.04 88.62 1.41 Allowed 'General case' 0 N--CA 1.445 -0.693 0 CA-C-O 121.215 0.531 . . . . 0.63 111.286 -178.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -61.56 -34.03 74.87 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 116.008 -0.542 . . . . 2.36 110.523 178.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.502 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 4.9 m -136.67 -84.93 0.34 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.94 -0.304 . . . . 0.3 111.769 176.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.648 HG12 ' O ' ' A' ' 13' ' ' DBB . 24.5 pt -63.82 -29.94 48.63 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.375 0 CA-C-N 115.773 -0.649 . . . . 1.88 111.993 -167.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 51.5 t . . . . . 0 N--CA 1.478 0.97 0 CA-C-O 120.0 -0.048 . . . . 3.15 110.957 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.502 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.563 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 9.6 t80 -70.51 101.33 1.97 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.742 -0.663 . . . . 1.03 110.521 178.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . 0.675 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.507 ' H ' ' HD2' ' A' ' 6' ' ' PRO . 6.5 mp -105.94 -39.72 0.17 Allowed Pre-proline 0 CA--C 1.544 0.732 0 N-CA-C 114.936 1.458 . . . . 2.45 114.936 -170.608 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.738 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 21.6 Cg_endo -67.59 152.64 77.97 Favored 'Trans proline' 0 C--N 1.356 0.953 0 C-N-CA 121.851 1.701 . . . . 2.01 112.823 -173.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.471 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -119.15 87.25 0.41 Allowed Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.804 -0.712 . . . . 4.79 112.851 -177.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -113.97 -43.34 0.8 Allowed Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 110.943 -0.863 . . . . 4.78 110.943 175.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -119.35 36.97 3.31 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 109.893 -1.283 . . . . 3.95 109.893 172.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.471 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 112.24 -89.09 0.52 Allowed Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 110.507 -1.037 . . . . 1.34 110.507 -172.126 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.654 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 0.4 OUTLIER -151.35 150.4 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.956 0 CA-C-O 121.486 0.66 . . . . 1.11 110.088 173.112 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.738 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -59.9 147.12 39.72 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 114.127 -1.397 . . . . 0.54 110.399 172.649 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.489 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.439 ' O ' ' HG ' ' A' ' 14' ' ' LEU . 30.4 tp -74.02 84.1 1.77 Allowed 'General case' 0 N--CA 1.444 -0.729 0 CA-C-O 121.449 0.642 . . . . 0.63 111.086 -178.432 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -62.92 -32.69 74.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.836 0.351 . . . . 2.36 110.887 179.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.563 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 3.7 m -136.55 -87.39 0.32 Allowed 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.681 -0.408 . . . . 0.3 111.896 178.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.459 HD11 ' HA ' ' A' ' 2' ' ' DBB . 0.5 OUTLIER -65.24 -28.96 45.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 115.205 -0.907 . . . . 1.88 111.105 -169.361 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.546 ' HA ' ' C ' ' A' ' 2' ' ' DBB . 40.1 t . . . . . 0 N--CA 1.481 1.123 0 N-CA-C 111.305 0.113 . . . . 3.15 111.305 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.546 ' C ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.416 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 12.0 t80 -76.81 98.91 4.98 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.007 -0.542 . . . . 1.03 109.565 174.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . 0.644 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.479 ' H ' ' CD ' ' A' ' 6' ' ' PRO . 5.5 mp -113.9 -43.65 0.07 OUTLIER Pre-proline 0 CA--C 1.541 0.632 0 N-CA-C 113.656 0.984 . . . . 2.45 113.656 -172.198 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.689 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 51.2 Cg_exo -61.08 146.1 98.09 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.18 1.92 . . . . 2.01 113.283 -173.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -76.28 75.11 1.61 Allowed Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.535 -0.757 . . . . 4.79 113.004 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -119.31 75.98 0.3 Allowed Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 110.421 -1.072 . . . . 4.78 110.421 174.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.51 39.5 5.3 Favored Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 110.518 -1.033 . . . . 3.95 110.518 -171.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.455 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 93.73 -83.28 1.03 Allowed Glycine 0 N--CA 1.444 -0.819 0 N-CA-C 110.455 -1.058 . . . . 1.34 110.455 -172.304 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.2 m -132.84 149.33 31.79 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.814 0 CA-C-O 121.822 0.82 . . . . 1.11 110.987 173.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.689 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -61.04 148.15 41.23 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 113.211 -1.813 . . . . 0.54 109.451 168.811 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.458 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 46.0 tp -73.56 86.54 1.59 Allowed 'General case' 0 N--CA 1.441 -0.889 0 CA-C-O 121.318 0.58 . . . . 0.63 110.95 -178.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -59.69 -36.41 76.45 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.451 -0.34 . . . . 2.36 110.659 178.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.458 ' HB2' ' HA ' ' A' ' 13' ' ' DBB . 3.4 m -134.58 -85.31 0.41 Allowed 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 112.123 0.416 . . . . 0.3 112.123 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.45 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER -63.75 -30.51 50.09 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 115.431 -0.804 . . . . 1.88 111.582 -168.691 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.459 ' HB3' ' HA ' ' A' ' 2' ' ' DBB . 1.9 t . . . . . 0 N--CA 1.478 0.964 0 N-CA-C 109.397 -0.594 . . . . 3.15 109.397 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.459 ' HA ' ' HB3' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.807 ' HD2' ' HB3' ' A' ' 18' ' ' CYS . 22.9 t80 -64.68 111.12 2.61 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.883 -0.598 . . . . 1.03 110.255 176.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . 0.584 ' HB2' HD23 ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.584 HD23 ' HB2' ' A' ' 4' ' ' DBB . 1.1 pt? -178.3 -36.87 0.0 OUTLIER Pre-proline 0 CA--C 1.546 0.796 0 N-CA-C 112.681 0.623 . . . . 2.45 112.681 178.394 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.574 ' CD ' ' HG ' ' A' ' 5' ' ' LEU . 3.3 Cg_endo -91.97 -159.02 0.07 OUTLIER 'Trans proline' 0 C--N 1.366 1.462 0 C-N-CA 122.222 1.948 . . . . 2.01 112.405 -175.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.43 38.76 1.42 Allowed Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 121.035 -0.603 . . . . 4.79 112.465 -177.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -70.17 -92.51 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.909 -0.663 . . . . 4.78 111.893 179.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -81.74 80.98 1.7 Allowed Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 110.738 -0.945 . . . . 3.95 110.738 173.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.71 -84.49 0.66 Allowed Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.273 -0.731 . . . . 1.34 111.273 -171.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.608 HG23 ' H ' ' A' ' 12' ' ' CYS . 0.0 OUTLIER -128.84 -88.48 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 120.941 0.401 . . . . 1.11 110.535 173.667 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.608 ' H ' HG23 ' A' ' 11' ' ' VAL . 1.5 t -173.84 81.23 0.04 OUTLIER 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 107.74 -1.208 . . . . 0.54 107.74 -174.476 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.613 ' O ' ' HB ' ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 52.9 tp -73.96 66.77 1.2 Allowed 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 121.64 0.733 . . . . 0.63 109.654 177.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . 0.464 ' H ' ' C ' ' A' ' 13' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.7 tp10 -59.72 -32.59 70.68 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.382 0.61 . . . . 2.36 109.617 174.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.807 ' HB3' ' HD2' ' A' ' 3' ' ' PHE . 1.4 m -132.79 -69.32 0.57 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.54 -0.755 . . . . 0.3 110.686 179.151 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.613 ' HB ' ' O ' ' A' ' 13' ' ' DBB . 44.2 mm -103.77 -77.33 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 CA-C-N 114.04 -1.436 . . . . 1.88 110.996 -169.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.544 ' HB3' ' HA ' ' A' ' 2' ' ' DBB . 2.0 t . . . . . 0 N--CA 1.476 0.848 0 N-CA-C 109.223 -0.658 . . . . 3.15 109.223 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.544 ' HA ' ' HB3' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -67.28 107.09 2.25 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.066 -0.515 . . . . 1.03 110.616 178.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . 0.612 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.673 ' H ' HD23 ' A' ' 5' ' ' LEU . 1.0 OUTLIER -74.11 -35.0 2.18 Favored Pre-proline 0 CA--C 1.55 0.959 0 N-CA-C 114.589 1.329 . . . . 2.45 114.589 -174.917 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.986 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 3.6 Cg_exo -78.56 -168.69 0.65 Allowed 'Trans proline' 0 C--N 1.361 1.193 0 C-N-CA 122.154 1.903 . . . . 2.01 111.775 -177.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.512 ' HA2' ' HA ' ' A' ' 11' ' ' VAL . . . -112.33 -91.2 1.97 Allowed Glycine 0 N--CA 1.442 -0.922 0 C-N-CA 120.465 -0.874 . . . . 4.79 112.586 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.24 38.51 96.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.959 -0.639 . . . . 4.78 112.078 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.72 36.72 1.37 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.939 -0.648 . . . . 3.95 111.483 -175.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.434 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 114.35 -88.96 0.49 Allowed Glycine 0 N--CA 1.445 -0.717 0 N-CA-C 111.319 -0.712 . . . . 1.34 111.319 -175.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.582 ' HA ' ' O ' ' A' ' 6' ' ' PRO . 3.1 m -149.72 150.09 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.867 0 CA-C-O 121.745 0.783 . . . . 1.11 110.199 175.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.986 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -64.95 144.52 57.23 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 113.787 -1.551 . . . . 0.54 109.927 171.746 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.595 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.41 ' HB2' ' O ' ' A' ' 11' ' ' VAL . 40.9 tp -71.74 89.42 1.03 Allowed 'General case' 0 N--CA 1.443 -0.789 0 CA-C-O 121.445 0.641 . . . . 0.63 111.797 -174.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 21.1 tp10 -59.78 -40.23 87.55 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 116.285 -0.416 . . . . 2.36 110.348 177.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.411 ' HB2' ' HA ' ' A' ' 13' ' ' DBB . 7.7 m -131.77 -82.96 0.51 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 112.126 0.417 . . . . 0.3 112.126 176.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.595 HG12 ' O ' ' A' ' 13' ' ' DBB . 28.6 pt -61.21 -27.38 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 N-CA-C 112.674 0.62 . . . . 1.88 112.674 -167.403 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.56 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 40.5 t . . . . . 0 N--CA 1.479 0.995 0 CA-C-O 119.874 -0.108 . . . . 3.15 110.873 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.56 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.564 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 10.8 t80 -72.46 110.29 6.76 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.522 -0.548 . . . . 1.03 109.522 175.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . 0.704 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.488 ' N ' ' HD3' ' A' ' 6' ' ' PRO . 3.7 pp -69.11 -28.21 1.52 Allowed Pre-proline 0 CA--C 1.552 1.035 0 N-CA-C 115.667 1.728 . . . . 2.45 115.667 -172.4 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.981 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 3.9 Cg_exo -83.74 158.18 14.03 Favored 'Trans proline' 0 C--N 1.36 1.167 0 C-N-CA 121.897 1.731 . . . . 2.01 112.331 -176.712 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.428 ' HA2' ' O ' ' A' ' 10' ' ' GLY . . . -109.73 73.53 0.21 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.92 -0.657 . . . . 4.79 112.563 -177.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -112.78 94.9 0.75 Allowed Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 111.301 -0.72 . . . . 4.78 111.301 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 80.16 36.68 23.79 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 110.733 -0.947 . . . . 3.95 110.733 -171.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.428 ' O ' ' HA2' ' A' ' 7' ' ' GLY . . . 108.16 -93.1 0.78 Allowed Glycine 0 N--CA 1.443 -0.838 0 N-CA-C 111.082 -0.807 . . . . 1.34 111.082 -175.106 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 8.5 m -146.94 154.31 12.0 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.925 0 CA-C-O 121.707 0.765 . . . . 1.11 110.26 174.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.981 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -71.66 147.49 47.43 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 113.997 -1.456 . . . . 0.54 109.358 171.165 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.48 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 55.1 tp -74.44 83.2 1.96 Allowed 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 121.246 0.546 . . . . 0.63 111.01 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -64.21 -34.02 77.13 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.676 0.274 . . . . 2.36 111.098 -179.215 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.564 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 3.1 m -133.75 -86.21 0.43 Allowed 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.28 -0.568 . . . . 0.3 112.498 -179.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.414 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.4 OUTLIER -63.46 -30.18 49.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 CA-C-N 115.045 -0.98 . . . . 1.88 111.879 -167.194 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.552 ' HB3' HD11 ' A' ' 19' ' ' ILE . 1.8 t . . . . . 0 N--CA 1.476 0.843 0 CA-C-O 118.877 -0.582 . . . . 3.15 109.568 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.536 ' HA ' ' HB3' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.561 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 3.4 t80 -68.14 93.77 0.46 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.174 0.512 . . . . 1.03 110.043 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.53 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 9.9 mp -58.86 -53.94 61.39 Favored Pre-proline 0 CA--C 1.538 0.489 0 N-CA-C 113.163 0.801 . . . . 2.45 113.163 -172.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.671 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 52.9 Cg_exo -55.87 146.12 69.35 Favored 'Trans proline' 0 C--N 1.358 1.06 0 C-N-CA 122.144 1.896 . . . . 2.01 112.872 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -127.39 97.73 0.48 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.086 -0.578 . . . . 4.79 112.749 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -179.81 -152.22 10.61 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.885 -0.674 . . . . 4.78 111.591 179.104 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.47 -32.28 68.02 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.079 -0.582 . . . . 3.95 111.81 177.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -110.97 99.01 1.09 Allowed Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.499 -0.64 . . . . 1.34 111.499 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.9 m -114.8 153.75 16.26 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.75 0 CA-C-O 122.044 0.926 . . . . 1.11 112.03 -176.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.671 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -69.4 142.88 53.79 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 113.392 -1.731 . . . . 0.54 109.563 170.919 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.45 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.405 ' O ' ' HG ' ' A' ' 14' ' ' LEU . 43.2 tp -73.85 83.84 1.68 Allowed 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.893 -0.594 . . . . 0.63 111.21 -176.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -61.57 -27.79 68.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.026 -0.534 . . . . 2.36 110.576 177.265 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.561 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 4.6 m -144.52 -85.34 0.13 Allowed 'General case' 0 C--O 1.233 0.212 0 N-CA-C 112.024 0.379 . . . . 0.3 112.024 177.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.552 HD11 ' HB3' ' A' ' 1' ' ' CYS . 0.5 OUTLIER -66.23 -28.97 45.21 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 CA-C-N 114.638 -1.164 . . . . 1.88 112.386 -166.661 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 0.6 OUTLIER . . . . . 0 N--CA 1.48 1.058 0 CA-C-O 119.213 -0.422 . . . . 3.15 109.879 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.578 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.571 ' CD2' ' HB3' ' A' ' 18' ' ' CYS . 4.9 t80 -67.74 111.68 4.4 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.669 -0.696 . . . . 1.03 109.24 173.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.984 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 85.2 mt -137.1 -68.18 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.411 0 C-N-CA 121.317 -0.153 . . . . 2.45 111.123 175.017 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.984 ' HD3' ' HB2' ' A' ' 5' ' ' LEU . 27.4 Cg_exo -63.46 167.07 13.78 Favored 'Trans proline' 0 C--N 1.356 0.963 0 C-N-CA 122.367 2.045 . . . . 2.01 112.381 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -107.53 -25.08 6.15 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.91 -0.662 . . . . 4.79 112.399 -179.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -124.19 149.74 16.95 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.55 -0.833 . . . . 4.78 112.384 179.389 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 66.88 -128.69 29.25 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 121.078 -0.582 . . . . 3.95 112.228 179.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.411 ' O ' ' HG2' ' A' ' 6' ' ' PRO . . . -66.96 93.66 0.22 Allowed Glycine 0 N--CA 1.449 -0.452 0 N-CA-C 111.367 -0.693 . . . . 1.34 111.367 176.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.702 ' O ' ' HB3' ' A' ' 12' ' ' CYS . 2.2 m -88.57 -16.81 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.846 0 N-CA-C 113.186 0.809 . . . . 1.11 113.186 -171.513 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.702 ' HB3' ' O ' ' A' ' 11' ' ' VAL . 1.7 t 78.87 120.41 0.05 Allowed 'General case' 0 C--N 1.322 -0.594 0 O-C-N 124.232 0.958 . . . . 0.54 108.809 -173.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.411 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 39.4 tp -73.75 93.02 2.06 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-O 121.444 0.64 . . . . 0.63 111.212 -177.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.6 tp10 -59.77 -31.73 69.93 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 115.542 -0.754 . . . . 2.36 110.603 176.288 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.571 ' HB3' ' CD2' ' A' ' 3' ' ' PHE . 7.8 m -142.91 -82.03 0.19 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.006 0.431 . . . . 0.3 111.829 177.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.428 ' H ' ' HB2' ' A' ' 18' ' ' CYS . 0.2 OUTLIER -66.95 -29.33 45.91 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-N 114.492 -1.231 . . . . 1.88 111.678 -167.398 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.518 ' HB3' ' HA ' ' A' ' 2' ' ' DBB . 3.1 t . . . . . 0 N--CA 1.477 0.882 0 N-CA-C 108.747 -0.834 . . . . 3.15 108.747 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.518 ' HA ' ' HB3' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.858 ' HD2' ' HB3' ' A' ' 18' ' ' CYS . 18.1 t80 -71.73 120.97 18.08 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.697 -0.853 . . . . 1.03 108.697 170.69 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.411 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 73.7 mt -67.72 -55.97 12.96 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 120.774 -0.37 . . . . 2.45 111.541 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.696 ' HG2' ' HA ' ' A' ' 11' ' ' VAL . 36.3 Cg_endo -65.67 154.9 71.8 Favored 'Trans proline' 0 C--N 1.354 0.821 0 C-N-CA 121.806 1.671 . . . . 2.01 111.992 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -114.85 -27.46 3.23 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.791 -0.718 . . . . 4.79 112.12 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.17 153.03 17.0 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.811 -0.709 . . . . 4.78 112.179 178.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 72.98 -141.51 30.43 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.038 -0.601 . . . . 3.95 112.561 179.567 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -69.33 90.11 0.28 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 121.407 -0.425 . . . . 1.34 112.249 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.696 ' HA ' ' HG2' ' A' ' 6' ' ' PRO . 35.7 m -95.84 160.74 2.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.93 0.872 . . . . 1.11 112.178 -175.546 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -70.06 93.12 0.78 Allowed 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 113.247 -1.797 . . . . 0.54 110.061 175.315 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.661 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 39.4 tp -73.13 92.18 1.69 Allowed 'General case' 0 N--CA 1.444 -0.765 0 CA-C-O 121.233 0.539 . . . . 0.63 111.649 -177.282 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 73.9 tt0 -59.59 -34.17 72.38 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.972 -0.558 . . . . 2.36 110.666 177.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.858 ' HB3' ' HD2' ' A' ' 3' ' ' PHE . 10.0 m -136.86 -84.71 0.34 Allowed 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 111.843 0.312 . . . . 0.3 111.843 176.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.661 HG12 ' O ' ' A' ' 13' ' ' DBB . 31.4 pt -64.1 -27.62 43.14 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.44 0 CA-C-N 115.738 -0.665 . . . . 1.88 112.072 -168.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.721 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 0.7 OUTLIER . . . . . 0 N--CA 1.477 0.907 0 N-CA-C 109.675 -0.491 . . . . 3.15 109.675 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.721 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -65.78 103.43 0.9 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.994 -0.548 . . . . 1.03 110.959 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . 0.416 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.4 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 96.8 mt -59.71 -54.83 51.91 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 112.983 0.734 . . . . 2.45 112.983 -173.548 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.478 ' HG2' ' H ' ' A' ' 12' ' ' CYS . 29.1 Cg_endo -63.78 150.88 87.42 Favored 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 121.856 1.704 . . . . 2.01 112.333 -178.695 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.577 ' HA2' HG12 ' A' ' 11' ' ' VAL . . . -150.2 50.47 0.54 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.951 -0.642 . . . . 4.79 112.28 -177.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.24 34.82 3.55 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.775 -0.726 . . . . 4.78 112.405 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.4 -89.48 0.49 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.681 -0.771 . . . . 3.95 111.852 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.45 89.26 0.72 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.788 -0.72 . . . . 1.34 111.304 174.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.577 HG12 ' HA2' ' A' ' 7' ' ' GLY . 30.5 m -89.41 162.44 2.53 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.797 0 CA-C-O 122.205 1.002 . . . . 1.11 111.809 -174.125 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.478 ' H ' ' HG2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -72.86 96.99 2.17 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-N 113.524 -1.671 . . . . 0.54 109.235 171.967 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.642 ' O ' ' HB ' ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 48.0 tp -73.79 74.78 1.59 Allowed 'General case' 0 N--CA 1.438 -1.031 0 CA-C-O 121.435 0.636 . . . . 0.63 109.717 178.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 -59.4 -37.09 77.11 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 115.776 -0.647 . . . . 2.36 109.678 175.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.521 ' HB2' ' H ' ' A' ' 19' ' ' ILE . 1.5 m -129.23 -86.34 0.55 Allowed 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.739 -0.664 . . . . 0.3 110.342 175.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.642 ' HB ' ' O ' ' A' ' 13' ' ' DBB . 28.4 mm -68.12 -77.54 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.566 0 CA-C-N 114.702 -1.135 . . . . 1.88 111.558 -175.112 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.541 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 40.4 t . . . . . 0 N--CA 1.475 0.806 0 CA-C-O 119.992 -0.052 . . . . 3.15 111.066 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.541 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.491 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 13.3 t80 -68.46 108.41 3.27 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.703 -0.681 . . . . 1.03 110.084 177.008 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . 0.415 ' HA ' ' O ' ' A' ' 12' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.59 ' HB2' ' HD3' ' A' ' 6' ' ' PRO . 7.9 mp -60.56 -53.28 66.1 Favored Pre-proline 0 N--CA 1.467 0.409 0 N-CA-C 112.53 0.567 . . . . 2.45 112.53 -174.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.743 ' HD2' ' HB3' ' A' ' 12' ' ' CYS . 14.8 Cg_exo -68.7 92.58 0.43 Allowed 'Trans proline' 0 C--N 1.355 0.921 0 C-N-CA 122.074 1.849 . . . . 2.01 111.64 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.571 ' HA2' HG12 ' A' ' 11' ' ' VAL . . . -103.07 83.88 0.45 Allowed Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.81 -0.709 . . . . 4.79 112.119 -177.404 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -170.87 86.07 0.08 OUTLIER Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 111.466 -0.654 . . . . 4.78 111.466 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 70.86 -90.6 0.41 Allowed Glycine 0 N--CA 1.451 -0.351 0 N-CA-C 111.456 -0.658 . . . . 3.95 111.456 -175.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.41 99.96 0.77 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.858 -0.687 . . . . 1.34 111.425 173.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.571 HG12 ' HA2' ' A' ' 7' ' ' GLY . 33.9 m -113.64 152.66 15.3 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.702 0 CA-C-O 121.995 0.902 . . . . 1.11 111.883 -175.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.743 ' HB3' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER -78.2 136.48 37.81 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 113.294 -1.776 . . . . 0.54 108.866 169.791 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.445 ' O ' HG22 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 36.8 tp -72.4 91.17 1.34 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.398 0.618 . . . . 0.63 111.784 -174.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -59.32 -35.66 74.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.817 -0.629 . . . . 2.36 109.982 176.025 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.491 ' HB3' ' HB3' ' A' ' 3' ' ' PHE . 34.6 m -134.9 -87.82 0.37 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.332 -0.394 . . . . 0.3 111.569 175.666 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.445 HG22 ' O ' ' A' ' 13' ' ' DBB . 4.1 tt -55.91 -31.09 29.59 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-N 115.212 -0.904 . . . . 1.88 112.989 -170.407 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 42.4 t . . . . . 0 N--CA 1.478 0.952 0 CA-C-O 120.071 -0.014 . . . . 3.15 110.972 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.564 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.827 ' HD2' ' HB3' ' A' ' 18' ' ' CYS . 16.3 t80 -67.81 110.86 3.99 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.853 -0.612 . . . . 1.03 109.841 177.291 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.47 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 95.7 mt -71.64 -53.8 7.07 Favored Pre-proline 0 CA--C 1.537 0.474 0 N-CA-C 112.379 0.511 . . . . 2.45 112.379 -176.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.47 ' HD2' ' N ' ' A' ' 5' ' ' LEU . 20.3 Cg_endo -61.2 144.04 98.75 Favored 'Trans proline' 0 C--N 1.356 0.924 0 C-N-CA 122.067 1.844 . . . . 2.01 112.244 -179.258 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -129.18 91.36 0.32 Allowed Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.034 -0.603 . . . . 4.79 112.437 -179.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 175.96 -155.87 20.36 Favored Glycine 0 N--CA 1.449 -0.496 0 N-CA-C 111.276 -0.729 . . . . 4.78 111.276 179.509 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.11 93.8 0.78 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.832 -0.699 . . . . 3.95 111.75 177.052 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 114.2 77.96 0.79 Allowed Glycine 0 N--CA 1.444 -0.801 0 N-CA-C 111.011 -0.835 . . . . 1.34 111.011 -175.405 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 21.8 m -109.1 167.02 4.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 122.052 0.929 . . . . 1.11 112.339 -175.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -67.2 138.88 57.3 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 112.961 -1.927 . . . . 0.54 109.346 171.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.426 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 32.8 tp -72.68 94.49 1.75 Allowed 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 115.992 -0.549 . . . . 0.63 111.632 -176.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -59.86 -32.37 70.64 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.761 -0.654 . . . . 2.36 110.462 176.468 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.827 ' HB3' ' HD2' ' A' ' 3' ' ' PHE . 14.4 m -143.4 -85.72 0.14 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.288 -0.414 . . . . 0.3 111.814 179.116 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.484 HD13 ' O ' ' A' ' 19' ' ' ILE . 0.2 OUTLIER -64.97 -31.22 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 CA-C-N 114.981 -1.009 . . . . 1.88 111.188 -168.307 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.53 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 43.4 t . . . . . 0 N--CA 1.478 0.967 0 CA-C-O 119.825 -0.131 . . . . 3.15 110.729 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.53 ' O ' ' HA ' ' A' ' 1' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.743 ' HD2' ' HB3' ' A' ' 18' ' ' CYS . 48.6 t80 -63.1 106.8 0.91 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.629 -0.714 . . . . 1.03 110.223 175.049 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . 0.425 ' HB2' ' H ' ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.454 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 97.8 mt -67.74 -53.6 20.86 Favored Pre-proline 0 CA--C 1.538 0.513 0 N-CA-C 111.866 0.321 . . . . 2.45 111.866 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.454 ' HD2' ' N ' ' A' ' 5' ' ' LEU . 34.5 Cg_endo -65.26 151.45 85.31 Favored 'Trans proline' 0 C--N 1.356 0.93 0 C-N-CA 121.978 1.785 . . . . 2.01 112.455 -179.696 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -127.41 29.92 4.17 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.046 -0.597 . . . . 4.79 112.287 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -116.27 -136.48 5.85 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.024 -0.608 . . . . 4.78 112.345 -179.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -71.05 -85.01 0.18 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.149 -0.548 . . . . 3.95 112.482 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -70.64 92.7 0.44 Allowed Glycine 0 N--CA 1.453 -0.225 0 C-N-CA 121.164 -0.541 . . . . 1.34 112.005 178.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 19.2 m -107.05 -177.19 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.509 -0.628 0 CA-C-O 122.146 0.974 . . . . 1.11 112.242 -175.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.89 142.11 29.94 Favored 'General case' 0 N--CA 1.435 -1.211 0 CA-C-N 113.46 -1.7 . . . . 0.54 109.344 176.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.69 ' O ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 29.8 tp -72.64 87.34 1.23 Allowed 'General case' 0 N--CA 1.445 -0.712 0 CA-C-O 121.193 0.521 . . . . 0.63 111.356 -177.058 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -62.77 -30.97 71.85 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.35 -0.386 . . . . 2.36 110.792 179.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.743 ' HB3' ' HD2' ' A' ' 3' ' ' PHE . 4.8 m -138.67 -83.88 0.28 Allowed 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 112.175 0.435 . . . . 0.3 112.175 177.311 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.69 HG12 ' O ' ' A' ' 13' ' ' DBB . 21.5 pt -67.16 -29.42 45.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 115.606 -0.725 . . . . 1.88 111.969 -167.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 2' ' ' DBB . 45.7 t . . . . . 0 N--CA 1.477 0.902 0 CA-C-O 119.943 -0.075 . . . . 3.15 110.941 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' DBB . . . . . 0.621 ' HA ' HG12 ' A' ' 19' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.454 ' HB3' ' HB3' ' A' ' 18' ' ' CYS . 31.1 t80 -68.69 102.45 1.51 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.77 -0.65 . . . . 1.03 110.372 178.008 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' DBB . . . . . 0.484 ' HB2' ' H ' ' A' ' 5' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.484 ' H ' ' HB2' ' A' ' 4' ' ' DBB . 4.3 mm? -61.41 -58.17 20.43 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 118.112 0.415 . . . . 2.45 110.855 179.073 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.675 ' HB2' HG12 ' A' ' 11' ' ' VAL . 76.5 Cg_endo -75.11 149.72 36.66 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 121.415 1.41 . . . . 2.01 111.133 174.081 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -133.79 28.49 3.22 Favored Glycine 0 CA--C 1.518 0.222 0 C-N-CA 120.64 -0.791 . . . . 4.79 112.928 -177.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.87 -90.31 2.16 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.835 -0.698 . . . . 4.78 113.021 -178.098 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.8 -94.1 2.24 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.735 -0.745 . . . . 3.95 112.534 -177.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.579 ' HA2' HD22 ' A' ' 14' ' ' LEU . . . -70.94 86.31 0.38 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 121.022 -0.609 . . . . 1.34 111.597 177.224 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.675 HG12 ' HB2' ' A' ' 6' ' ' PRO . 34.7 m -120.96 176.01 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.706 0 CA-C-O 122.096 0.951 . . . . 1.11 112.614 -171.379 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -69.42 132.29 46.11 Favored 'General case' 0 N--CA 1.432 -1.331 0 CA-C-N 112.785 -2.007 . . . . 0.54 109.167 170.316 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' DBB . . . . . 0.452 ' HA ' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.579 HD22 ' HA2' ' A' ' 10' ' ' GLY . 36.6 tp -74.1 87.25 1.89 Allowed 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 121.323 0.582 . . . . 0.63 111.144 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' DBB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -60.45 -29.07 68.79 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.266 -0.424 . . . . 2.36 110.33 177.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.454 ' HB3' ' HB3' ' A' ' 3' ' ' PHE . 3.5 m -143.79 -82.18 0.17 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.313 -0.403 . . . . 0.3 111.737 177.24 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.621 HG12 ' HA ' ' A' ' 2' ' ' DBB . 0.1 OUTLIER -63.78 -32.2 56.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 CA-C-N 115.324 -0.853 . . . . 1.88 111.719 -167.508 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' TEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_